Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S1
S U P P L E M E N T A R T I C L E
Recommendations for the Management
of Herpes Zoster
Robert H. Dworkin,1,2Robert W. Johnson,18Judith Breuer,19John W. Gnann,5,7Myron J. Levin,8Miroslav Backonja,9
Robert F. Betts,3Anne A. Gershon,4Maija L. Haanpa ¨a ¨,22Michael W. McKendrick,20Turo J. Nurmikko,21
Anne Louise Oaklander,10Michael N. Oxman,12Deborah Pavan-Langston,11Karin L. Petersen,14
Michael C. Rowbotham,14Kenneth E. Schmader,15Brett R. Stacey,16Stephen K. Tyring,17Albert J. M. van Wijck,23
Mark S. Wallace,13Sawko W. Wassilew,24and Richard J. Whitley6
University, New York, New York; Departments of
Affairs Medical Center, Birmingham, Alabama;
Massachusetts; Departments of
of California, San Francisco;
Laboratory, Queen Mary College, London,
21Department of Neurological Science, University of Liverpool, Liverpool, United Kingdom;
and Neurology, Helsinki University Hospital, Helsinki, Finland;
24Dermatologische Klinik, Klinikum Krefeld, Krefeld, Germany
3Medicine, University of Rochester, Rochester, and
8Department of Pediatrics, University of Colorado, Denver;
10Department of Neurology, Harvard University, and
15Department of Medicine, Duke University, Durham, North Carolina;
17University of Texas Health Science Center, Houston;
20Department of Infection and Tropical Medicine, Royal Hallamshire Hospital, Sheffield, and
4Department of Pediatrics, Columbia
6Pediatrics, University of Alabama at Birmingham, and
9Department of Neurology, University of
11Department of Ophthalmology, Harvard Medical School, Boston,
13Anesthesiology, University of California, San Diego, and
14Department of Neurology, University
16Department of Anesthesiology, University of
18Department of Anesthesiology, University of Bristol, Bristol,
22Departments of Anesthesiology and Intensive Care
23Pain Clinic, University of Utrecht Medical Center, Utrecht, The Netherlands; and
The objective of this article is to provide evidence-based recommendations for the management of patients
with herpes zoster (HZ) that take into account clinical efficacy, adverse effects, impact on quality of life, and
costs of treatment. Systematic literature reviews, published randomized clinical trials, existing guidelines, and
the authors’ clinical and research experience relevant to the management of patients with HZ were reviewed
at a consensus meeting. The results of controlled trials and the clinical experience of the authors support the
use of acyclovir, brivudin (where available), famciclovir, and valacyclovir as first-line antiviral therapy for the
treatment of patients with HZ. Specific recommendations for the use of these medications are provided. In
addition, suggestions are made for treatments that, when used in combination with antiviral therapy, may
further reduce pain and other complications of HZ.
After a primary varicella-zoster virus (VZV) infection
(termed “varicella” or “chickenpox”), the virus estab-
lishes latency in dorsal root and cranial nerve ganglia.
Herpes zoster (HZ), also known as “shingles,” results
from reactivation of VZV and its spread from a single
ganglion to the neural tissue of the affected segment
and the corresponding cutaneous dermatome .
The objective of this supplement to Clinical Infec-
Reprints or correspondence: Dr. Robert H. Dworkin, Dept. of Anesthesiology,
University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave., Box
604, Rochester, NY 14642 (email@example.com).
Clinical Infectious Diseases2007;44:S1–26
? 2006 by the Infectious Diseases Society of America. All rights reserved.
tious Diseases is to improve the care of patients with
HZ by providing practical, evidence-based recom-
mendations that take into account clinical efficacy,
adverse effects, impact on quality of life, and costs
of treatment. Pharmacologic management is empha-
sized, because few nonpharmacologic approacheshave
been evaluated in randomized controlled trials. These
recommendations apply only to the acute phase of
HZ; detailed recommendations for the treatment of
postherpetic neuralgia (PHN), the most common
complication of HZ, appear elsewhere [2, 3]. We de-
scribe the pathogenesis, epidemiological aspects, clin-
ical aspects, and complications of HZ, and then we
review the literature on the treatment of HZ and pre-
sent specific treatment recommendations.
S2 • CID 2007:44 (Suppl 1) • Dworkin et al.
Pathogenesis of HZ
Epidemiological Aspects of HZ
Clinical Aspects of HZ
Differential Diagnosis and Laboratory Testing
Complications of HZ
HZ Ophthalmicus with Delayed Contralateral
Methods Used for Developing Treatment
Data Sources and Study Selection
Treatment of Immunocompetent Patients
Recommendations for Antiviral Therapy
Supplementing Antiviral Therapy
Recommendations for Supplementing Antiviral Therapy
Treatment of Immunocompromised Patients
HZ in the Setting of Malignancy or Organ Transplantation
HZ in HIV-Seropositive Patients
Treatment of Complicated Presentations of HZ
HZ Ophthalmicus and VZV Retinitis
Vulnerable and Frail Elderly Patients
Pregnant and Nursing Patients
Neurologic Complications of HZ
Recommendations for Future Research
PATHOGENESIS OF HZ
Nasopharyngeal replication of VZV, which occurs immediately
after primary infection, is followed by spread to adjacent lym-
phoid tissue, where the virus infects memory CD4+T cells,
which are abundant in tonsilar lymphoid tissue . Trafficking
of memory cells expressing cutaneous homing antigen and
CCR4 to the skin is thought to deliver virus to cutaneous
epithelia within a few days of infection . The localized rep-
lication in epithelial cells is facilitated by down-regulation of
IFN-a within the infected cells and failure of induction of
adhesion molecules . At the same time, cell-to-cell spread
of virus appears to be contained forthefirstweekbyproduction
of IFN-a in adjacent epithelial cells [5, 6]. Thereafter, the virus
overcomes the innate defenses, and vesicles appear. Production
of cytokines and up-regulation of capillaryendothelialadhesion
factors attract migratory T cells that may further spread virus
before they contain viral replication .
Cell-free virus, which is present only in skin vesicles, is nec-
essary for the infection of sensory nerve endings in epithelia.
This results in virus migration up sensory axons to establish
latency in sensory ganglia . The final assembly and envel-
opment of newly synthesized virions occurs within specialized
wrapping cisternae located in the trans-Golgi network [8, 9].
The concave face of each wrapping cisterna is rich in VZV
glycoproteins and becomes the viral envelope. The convex side
is rich in cellular proteins, such as cation-independentmannose
6-phosphate receptors, and the cisterna becomes a transport
vesicle containing the newly enveloped virion [8, 10].Inhuman
embryo lung fibroblasts, the presence of cation-independent
mannose 6-phosphate receptors on the convex faceofthewrap-
ping cisterna is postulated to route virions from the cell se-
[8, 11, 12] (figure 1). VZV also spreads quickly to adjacent
epidermal cells by inducing the fusion (mediated by glycopro-
teins H, L, B, and E) of virally infected cells with uninfected
neighboring cells . In contrast, the loss of cation-indepen-
dent mannose 6-phosphate receptors in keratinocytes in the
superficial epidermis allows for the accumulation of cell-free
virions, which are necessary for transmissionandestablishment
of latency .
A guinea pig model of latency and reactivation in vitro has
been developed. Neurons dissected from the myenteric plexus
are propagated in culture. In this model, infection of sensory
nerve endings with cell-associated virus causes lytic infection,
whereas cell-free virus establishes latency . Latently infected
human ganglia show restricted expression of 6 genes—ORF4,
ORF21, ORF29, ORF62, ORF63, and ORF66 [14–17]—none of
which code for glycoproteins, with 1 report of detection of
open reading frame (ORF) 18 transcripts ; the samepattern
of expression is found in latently infected guinea pig somatic
neurons . The addition of cell-associated virus, the product
of the ORF61 gene, or its herpes simplex virus (HSV) homo-
logue ICP0 to the guinea pig gut model results in VZV reac-
tivation and lytic infection . ORF 61 protein is absent from
cell-free virions, which are able to establish latency in the gut
ganglia. More recently, direct transfer of VZV has been dem-
onstrated from infected peripheral blood mononuclear cells to
ganglion tissue implanted into SCID-hu mice. Direct transfer
of virus to the ganglion and establishment of latency by this
route may, therefore, be possible .
In situ hybridization has shown the latent VZV genome to
be localized in ∼1%–7% of sensory ganglion neurons, at !10
copies/cell [19–21]. In addition to detection of messenger RNA
Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S3
(VZV). A, Primary envelopment. VZV nucleocapsids assemble in thenucleus,
bud through the inner nuclear membrane, and acquire atemporaryenvelope
before entering the perinuclear cisterna,whichiscontinuouswiththelumen
of the endoplasmic reticulum. The primary virion envelope fuses with the
membrane of the endoplasmic reticulum, delivering naked nucleocapsids
into the cytosol. B, Glycoprotein transport and virion assembly. VZV gly-
coproteins are synthesized in the rough endoplasmic reticulum (RER) and
compartment (IC) independently of newly assembled nucleocapsids. From
the RER, the glycoproteins, together with adhered tegument proteins, are
transported to the trans-Golgi network (TGN), where they concentrate in
the concave membrane of specialized wrapping TGN cisternae. The viral
nucleocapsids converge with the glycoproteins and tegument as the TGN
sacs wrap around the nucleocapsids and fuse, giving rise to mature virions
The VZV glycoprotein-rich membrane of the concave face of the wrapping
cisterna becomes the viral envelope. The membrane of the convex face is
rich in mannose 6-phosphate (Man-6-P) receptors and delimits a transport
vesicle that encloses the newly enveloped virion. Man-6-P receptors on the
membrane of the convex face of the wrapping cisterna are thought to route
viral particles from the cell secretory pathway to endosomes where the
virions are degraded. Illustration reproduced with permission from .
Intracellular transport and maturation of varicella-zoster virus
from the 6 ORFs mentioned, immunohistochemical studies
have shown the presence of protein products from ORFs 4, 21,
29, 62, 63, and 66 [17, 22, 23]. Moreover, these are located in
the cytoplasm of infected cells, whereas, in lytic infection, both
cytoplasmic and nuclear localization is evident. A working hy-
pothesis is that phosphorylation of immediate-early protein 62
by the protein kinase encoded by ORF66 preventstranslocation
of the former to the nucleus, which, in turn, interrupts the
cascade of viral transcription and replication . The addition
of ORF 61 protein to the latently infected guinea pig neuron
model results in translocation of immediate-early protein 62
and the ORF 29 protein to the nucleus. This causes transcrip-
tion of a, b, and g viral proteins and reestablishment of lytic
infection [7, 22].
The incidence of HZ increases with age and with othercauses
of decreased cellular immunity. Limiting dilution experiments
have established that reduced VZV T cell responder cell fre-
quency characterizes all conditions associated with increased
VZV reactivation . Much of the T cell response in latently
infected individuals is directed against glycoproteins E, H, B,
and I, as well as against transcriptional activators encoded by
ORFs 4, 10, 62, and 63. Boosting of the cell-mediated immune
response has been shown in mothers of children with varicella,
suggesting that exposure to antigenmaybeimportantformain-
taining immunity . Two studies have shown that the in-
cidence of HZ is lower in adults with greater contact with
children in their daily lives, which was considered to be a sur-
rogate for exposure to VZV [26, 27]. Proof that exposure to
exogenous antigen is protective came with the recent dem-
onstration that a live attenuated VZV vaccine reduced the in-
cidence of HZ and the burden of disease, compared with pla-
Reducing the occurrence of HZ will be crucial to eliminating
transmission of VZV. The force of infection (i.e., the rate at
which individuals acquire infection after exposure) is estimated
to be 20% for varicella leading to infection of children 2–4
years of age. By contrast, the estimated force of infection for
HZ causing varicella is 0.1% . Thus, susceptible children
are more likely to develop varicella from exposure to varicella
than from exposure to HZ. Nonetheless, HZ will become a
more common source of varicella as immunization programs
eliminate varicella; this is already evident in casesofnosocomial
varicella in the United Kingdom, where many cases arise from
contact with HZ rather than varicella .
EPIDEMIOLOGICAL ASPECTS OF HZ
Varicella typically occurs during childhood in temperate cli-
mates and during adolescence or early adulthood in tropical
areas . Latency is typically lifelong, and HZ is caused by
viral reactivation from the latent state. Second episodes of HZ
occur in ?5% of individuals but occur more frequentlyinthose
who are immunocompromised. Primary infection produces
long-term immunity to varicella. Protection from reactivation
depends on intact cell-mediated immunity, which declineswith
age (immunosenescence), during certain diseases (e.g., HIV
infection and some malignancies), and as a result of immu-
S4 • CID 2007:44 (Suppl 1) • Dworkin et al.
nosuppressive therapy (e.g., after organ transplantation, che-
motherapy, or steroid treatment). The survival of VZV in hu-
mans for several million years attests to its success.
Data from a number of sources consistently show that the
incidence of HZ increases with age. Although HZ is not rare
in young individuals, the median age of patients with HZ is
∼64 years, whereas the median age of the US population is ∼46
years. The incidence of HZ ranges from 1.2 to 3.4 cases per
1000 person-years in studies of immunocompetent individuals
in the community, but it increases to 3.9–11.8 cases per 1000
person-years among those 165 years of age [28, 32–36]. Some
[37, 38], but not all [39, 40], recent studies have found the
incidence of HZ to be increasing, although the explanation is
unclear. It is likely that the incidence of HZ will change further
over the coming decades, as a result of the increasing age of
the population, changes in therapy for malignant and auto-
immune diseases, and the increasing use of organ transplan-
tation, and, possibly, as a consequence of childhood varicella
In the developed world and elsewhere, significant increases
are occurring in the percentage of people who are elderly. In
the United Kingdom, 2001 census data showed that the pop-
ulation ?65 years of age numbered ∼9 million (16%), and the
projection for 2025 is 13 million. Among those ?65 years of
age, the proportion of people ?85 years of age has increased
from 7% in 1971 to 12% in 2004. Data from the Scientific
Registry of Transplant Recipients draft analysis has shown a
year-by-year increase in the number of solid-organ transplants
in the United States, with ∼12,000 conducted in 1988 and twice
that number conducted in 2003; all these patients receive im-
Recipients, personal communication, 13 January 2004).
Childhood vaccination to prevent varicella was introduced in
the United States in 1995, and other countries adopting this
strategy include Australia, Canada, Germany, Israel, Japan, and
South Korea. Epidemiological models suggest that a significant
opportunities for subclinical boosting, due to dramatic reduc-
tions in varicella incidence resulting from immunization [26, 41,
cell-mediated immunity and delays reactivation of latent virus,
adults with a history of varicella in regions where varicella in-
cidence has been markedly reduced by vaccination will be more
likely to develop HZ than will those livingwherevaricellaismore
common. The incidence of HZ may, therefore, increase signifi-
cantly, peaking ∼20 years after the initiation of childhood vac-
cination programs and only returning to prevaccination levels
after 40 years . Although the attenuated Oka vaccine virus
establishes neuronal latency in vaccine recipients, it appears to
reactivate and cause HZ much less frequently than does wild-
type VZV. Thus, it is expected that the incidence of HZ would
decrease as the number of adults infected with latent wild-type
virus decreases. Any increase in HZ incidence could be offset by
adult HZ vaccination, if its use becomes widespread. In a ran-
domized clinical trial of HZ vaccination compared with placebo
among nearly 39,000 adults ?60 years of age, the incidence of
HZ was reduced by 51.3% .
If vaccination of adults is widely adopted and produces re-
ductions in the incidence and burden of HZ in the community
that are comparable to those found in this trial , there
could be a dramatic reduction in HZ incidence in the decades
to come. Considering the potential impact of adult HZ vac-
cination and the long-term effect of childhood varicella vac-
cination, future generations may largely be spared the most
distressing complications of HZ.
CLINICAL ASPECTS OF HZ
The reactivation of VZV in ganglia may be a frequent event. In
the presence of adequateVZV-specificimmuneresponses—most
importantly, T cell–mediated immunity—reactivation eventsare
either prevented or quickly aborted. The outcomes of these re-
activations, thus, remain subclinical, although immunological
evidence of their existence can be detected . If the VZV
reactivation is not contained, as can occur with iatrogenic im-
munosuppression or age-related immunosenescence, then viral
replication ensues, resulting in ganglionitis and extensive infec-
tion and destruction of neurons and supporting cells [44, 45].
This significant infection and accompanying inflammatory re-
sponse is probably the origin of the prodromal pain that pre-
cedes the characteristic dermatomal eruption of HZ. Approx-
imately 70%–80% of patients with HZ describe prodromalpain
in the dermatome where skin lesions subsequently appear.Pro-
dromal pain may be constant or intermittent and frequent or
sporadic, and it may or may not interfere with sleep. The pain
often has a distinctive quality for each patient and is commonly
described as “burning,” “shooting,” “stabbing,”or“throbbing.”
Some patients describe the pain only when the involved area
is touched, whereas others complain primarily of pruritus. The
prodrome is typically 2–3 days in duration, but longer dura-
tions, of ?1 week, are not uncommon. Significant and pro-
longed prodromal pain not uncommonly leads to medical in-
vestigation for diseases characterized by pain in the area of the
prodrome (e.g., angina, cholecystitis,glaucoma,nephrolithiasis,
and spinal nerve compression).
The cause of the dermatomal pain becomes obvious when
the characteristic rash appears in that dermatome . The in-
terval from the onset of the prodrome to the appearance of
rash represents the time required for reactivated VZV to rep-
licate in the ganglion and to transit down the cutaneous nerve
to the nerve endings at the dermal-epidermal junction. There
is additional delay while VZV replicates in the skin and induces
sufficient necrosis and inflammatory response to causetherash.
Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S5
Thoracic herpes zoster (photograph provided by S.W.W.)
Cervical herpes zoster (photograph provided by A.L.O.)
The rash associated with HZ has a brief erythematous and
macular phase, which is often missed, after which papules rap-
idly appear. These papules develop intovesicleswithin1–2days,
and vesicles continue to appear for 3–4 days. At this point,
lesions of all types may be present (see figures 2–4). The lesions
tend to be grouped, and clusters are often seen where there are
branches of the cutaneous sensory nerve (e.g., in parasternal,
mid-axillary, and paraspinous areas, representing the anterior
and lateral branches of the anterior primary division as well as
the posterior division of a thoracic nerve). Pustulation of ves-
icles begins within 1 week of the onset of rash, if not sooner,
and is followed 3–5 days later by lesion ulceration and crusting.
The appearance of new vesicles for 11 week should raise con-
cern about an underlying immunodeficiency syndrome. Crusts
usually are gone by the end of 3 or 4 weeks, but scarring and
hypo- or hyperpigmentation may persist long after the HZ
resolves. Fewer than 20% of patients have significant systemic
symptoms, such as fever, headache, malaise, or fatigue. Lesions
on mucous membranes, where the epidermis is fragile rather
than thick and keratinized, do not usually form vesicles and
crusts but form shallow erythematous ulcers. Eruptions on the
mucosa may go entirely unnoticed.
HZ is a dermatomal illness that does not cross the midline
except where the normal representation of segmental nerves
does so to a limited extent. In immunocompetentpatients,only
a single dermatome is typically affected; however, normal var-
iations in innervation can lead to limited involvement of ad-
jacent dermatomes. In typical HZ, widespread involvement of
multiple dermatomes, especiallythosethatarewidelyseparated,
does not occur. The rash is usually accompanied by the same
pain experienced during the prodrome, but this acute pain can
worsen, improve, or appear for the first time during the cu-
taneous phase of HZ. Pruritis may be as common as pain in
patients with HZ, although it has received far less medical
attention . Some mild cases of HZ are characterized by
more pruritis than pain.
In the immunocompetent patient with HZ, there are nu-
S6 • CID 2007:44 (Suppl 1) • Dworkin et al.
Herpes zoster ophthalmicus (photograph provided by D.P.-L.)
man who presented with vesicles in the T8 distribution 4 weeks before
this photo was taken. The patient was treated with an antiviral agent
for 7 days and with analgesics as needed. As the rash resolved, this
bulge became apparent; it is consistent with motor damage by varicella-
zoster virus to the muscles of the abdomen (photograph provided by
T8 motor neuropathy in an otherwise healthy 59-year-old
merous additional potential findings associated with the pain
and rash. Motor nerves may be involved in 5%–15% of cases
in which the nerves (especially those in muscles in the extrem-
ities) can be examined adequately. By use of electromyography,
it is possible to show that muscles are involved in 50% of cases
. Obvious paresis typically improves over time and may
respond to physical therapy (figure 5). The geniculate ganglion
also contains latent VZV derived from facial, aural, and oral
lesions of varicella. Reactivation in the geniculate ganglion can
lead to facial nerve (VII) paralysis (because sensory and motor
nerves are conjoined in nerve VII), as a result of a bystander
effect. VZV and HSV account for the majority of cases of Bell
palsy (idiopathic facial paralysis). In the absence of skin lesions,
the etiologic role of VZV or HSV reactivation is not clinically
obvious and must be determined by use of laboratory methods
[48–50]. It has been suggested that, because of the involvement
of VZV or HSV, moderate or severe Bell palsy in adults should
be treated with antiviral therapy as well as adjunctive admin-
istration of corticosteroids; results of controlled trials, however,
have been conflicting [51–55].
Reactivation in the geniculate ganglion can produce skin
lesions in the mucocutaneous distribution of its peripheral
nerves, including the ear and the side of the tongue. These
findings, together with facial paralysis, constitute RamsayHunt
syndrome, in which various vestibulocochlear manifestations
occur when cranial nerve VIII is affected by a bystander effect
[56, 57]. Satisfactoryrecoveryofmusclefunctiondecreaseswith
the age of the patient and the severity of the paralysis at onset.
Symptomatic reactivation in other cranial nerves has been doc-
umented [58, 59].
Reactivation of VZV in sensory ganglia may be accompanied
by extraneural spread, and viremia is frequently detected by
PCR early after the onset of rash. Viremia disappears most
rapidly in patients who receive antiviral therapy and is typically
inconsequential, because the anamnestic immune response in
the immunocompetent host limits replication to the derma-
tomal infection. However, when there is relative immune in-
sufficiency, as may result from immunosenescence, there may
be vesicles and other viremia-related skin manifestations at a
distance from the affected dermatome. The likelihood and ex-
tent of so-called “cutaneous dissemination” increases with age
(figure 6). However, even with advanced age, symptomatic in-
fection of internal organs is very rare. In severely immuno-
compromised patients with HZ, viremia can lead to life-threat-
ening visceral infection.
Subclinical invasion of VZV into the CNS is not uncommon
in HZ. One-third of immunocompetent patients without clin-
ical symptoms of infection of the CNS had either PCR results
positive for VZV or anti-VZV IgG present when a CSF sample
was obtained within the first weeks after the rash onset. Leu-
kocytosis in the CSF was found in 46% of the patients. Sub-
clinical HZ-associated changes in the brain stem were found
on MRI in 53% of the patients with cranial or cervical HZ
. VZV is a common cause of aseptic meningitis, which can
present with or without rash that may precede or follow the
meningeal symptoms. The course of the disease is benign, with
complete recovery expected in 1–2 weeks .
Second cases of HZ are uncommon in immunologically in-
tact hosts, presumably because an episode of HZ will boost
immunity and thereby prevent subsequent symptomatic VZV
reactivations. The available data suggest that second cases of
HZ occur in ?5% of individuals, although this conclusion is
limited by the duration of follow-up, uncertainty of the di-
Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S7
Disseminated herpes zoster (photograph provided by S.K.T.)
agnoses, and incomplete information about comorbid disease
There is great interest in the concept of VZV reactivation
causing dermatomal pain in the absence of skin lesions, termed
“zoster sine herpete.” This concept has been supported by se-
rologic and PCR evidence of concurrent VZV reactivationdur-
ing acute pain syndromes [62–65]. In addition, a variety of
otherwise unexplained local sensory and motor abnormalities
have been ascribed to VZV reactivation without skin manifes-
tations. Consequently, it has been suggested that patients with
unexplained and atypical local pain syndromes might benefit
from antiviral therapy against VZV. A prospective study of 56
patients with such complaints in a general practice setting,
together with 81 matched control blood donors, was under-
taken; none of the study subjects developed a rash, and the
presence of positive serologic test results (for IgM, IgG, and
IgA) and positive PCR results from circulating leukocytes was
very similar to that seen in the control group , indicating
that the presence of unexplained dermatomal pain did not
identify clinical or subclinical reactivations. Thus, the routine
use of antiviral agents for this purpose is not supported, and
there is the added concern that such therapy might abort ap-
propriate investigation of the etiology of the pain.
Although HZ incidence increases with age,
as a reflection of the VZV-specific immune senescence that
characterizes aging, HZ also occurs in children. It has been
reported that children 10–14 years of age have a frequency of
HZ (50–100 cases per 105children per year) that is one-fifth
to one-tenth that observed in adults 55–65 years of age [32–
34, 67]. In general, HZ in children is less severe than that in
older patients and is much less likely to result in severe acute
and prolonged pain [67, 68]. Recognized risk factors for HZ
occurring during childhood are a history of maternal varicella
during the pregnancy or a history of primary varicella in the
first year of life, which are situations that can be assumed to
result in blunting of VZV-specific immune memory during
primary exposure of the child to VZV. Presumably, HZ in chil-
dren reflects some interference with the normal immunemech-
anisms that maintain latency of VZV—for example, transient
immune suppression after Epstein-Barr–virus or cytomegalo-
virus infection .
Differential diagnosis and laboratory testing.
rash has appeared, the diagnosis of HZ is generally apparent
from the clinical presentation. However, the recentlycompleted
trial of a vaccine to prevent HZ found that 20% of suspected
cases could not be confirmed by PCR . This reflects, in
part, intentional overdiagnosis to include mild and atypical
cases. Nevertheless, multiple studies from clinical diagnostic
laboratories indicate that as many as 10% of specimens sub-
mitted from patients with presumed HZ instead contain HSV
[69, 70]. Important elements in establishing the diagnosis by
observation include (1) painful or abnormal sensory prodrome
(not always present); (2) dermatomal distribution; (3) grouped
vesicles (however, in some cases, only papules willbeobserved);
(4) multiple sites filling the dermatome, especially where di-
visions of the sensory nerve are represented; (5) lack of history
S8 • CID 2007:44 (Suppl 1) • Dworkin et al.
distribution had recurred many times over the past several years, and this outbreak began 1 week before the photo was taken. A viral culture
demonstrated herpes simplex virus type 2. The patient was otherwise healthy, except for hypertension (photograph provided by S.K.T.).
Zosteriform herpes simplex in an elderly woman who presented with what she called “her recurrent shingles.” Vesicles in a lumbosacral
of a similar rash in the same distribution (to rule out recurrent
zosteriform herpes simplex; see figure 7); and (6) pain and
allodynia in the area of the rash. Allodynia, which is common
in both HZ and PHN, is pain evoked by a stimulus that does
not normally cause pain—for example, light brushing of the
affected area with a cotton swab.
Important alternative diagnoses that can be confused with
HZ include zosteriform herpes simplex and contact dermatitis,
especially toxic dermatitis from plant exposure (which tends
to be seasonal). Moreover,thevaccinetrialrevealedthatatypical
disease (absence of pain or minimal pain, limited area of der-
matomal involvement, failure of vesicles to appear) is not un-
common . Atypical manifestations of HZ can also occur
in immunocompromised patients. These features can include
prolonged course, lesions that are intermittently recurrent, in-
volvement of multiple dermatomes, and lesions that appear as
chronic crusts or verrucous nodules. When atypical lesions are
present (whether in an immunocompetent patient or an im-
munocompromised patient), or when there is potential con-
fusion as to whether VZV or HSV is the pathogen (e.g., when
there are lesions in the sacral area), diagnostic laboratory tests
should be utilized.
PCR is the most sensitive and specific test, but it isexpensive,
and it takes at least 1 day to obtain results. However, DNA
amplification is useful for the analysis of “old” and crusted
lesions. Immunohistochemical analysis of a skin scraping is
rapid (∼3 h) and relatively inexpensive; the sensitivity is ∼90%,
and the specificity is 95%. The sensitivity decreases when the
lesions are beyond the vesicular stage,andtheprocedurecannot
be used on crusts. Specimens must be properly obtained for
optimal laboratory diagnosis. Immunohistochemical analysis
can be formatted to diagnose HSV infection, as well as VZV
infection, from the slide submitted. Culture of the virus is very
specific, but the result is delayed (1–2 weeks), and VZV is
detected from only 60%–75% of specimens. It is not useful for
very long beyond the vesicular stage of the rash [71, 72].
COMPLICATIONS OF HZ
of HZ that usually occurs a few days after the onset of rash
but has been reported from days to weeks before or after the
skin eruption . It should be recognized, however, that CSF
pleocytosis is present in ∼50% of individuals with uncompli-
cated HZ, reflecting the local leptomeningitis that regularly
accompanies the disease. Encephalitis has occasionally been
documented in the absence of apparent cutaneous HZ and in
patients who received appropriate antiviral therapy during the
acute episode of HZ. Immunocompromised patients areclearly
at increased risk for the development of encephalitis [73, 74].
Other markers of increased risk for CNS involvement include
HZ in a cranial nerve dermatome or the presence of cutaneous
Acute VZV encephalitis is a rare complication
Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S9
dissemination. The clinical presentation is most often an acute
or subacute delirium accompanied byfewfocalneurologicsigns
. Other findings can include headache, meningismus,fever,
ataxia, and seizures. The rate of death due to HZ-associated
encephalitis varies from 0% to 25%, probably according to the
extent of immune compromise, with an average mortality rate
of ∼10% .
Chronic VZV encephalitis is seen almost exclusively in im-
munocompromised patients, especially patients withAIDSwho
have marked depletion of CD4+T cells . The onset of
encephalitis may occur months after an episode of HZ; 30%–
40% of these patients have no recognized history of cutaneous
VZV infection, which makes the diagnosis more difficult. The
clinical presentation is usually subacute, with headache, fever,
mental status changes, and seizures. Patients may have focal
neurologic defects, including aphasia, hemiplegia, and visual-
field cuts . MRI demonstrates plaque-like lesions in deep
white matter, changes consistent with demyelination, and late
development of ischemic or hemorrhagic infarcts of cortical
and subcortical gray and white matter . CSF examination
reveals mononuclear pleocytosis. VZV DNA has beenamplified
by PCR from the CSF of patients with chronic encephalitis
. Pathologic studies reveal multifocal leukoencephalopathy,
with lesions in the white matter near the gray-white junction,
small-vessel vasculitis, and demyelination . Patients often
have a clinical course of progressive deterioration and death,
although anecdotal reports have suggested some benefit from
high-dose intravenous acyclovir therapy [78, 79].
HZ ophthalmicus with delayed contralateral hemiparesis.
Stroke is a rare but serious complication of HZ that has been
reported in both immunocompetent and immunocompromi-
sed patients , including both children and adults . The
pathogenesis of this unusual disorder is thought to be direct
VZV invasion of large cerebral arteries by extension of virus
from smaller vessels that traversethetrigeminal-innervatedme-
ninges. This produces a necrotizing arteritis that can result in
vascular thrombosis or hemorrhage. The most frequently de-
scribed presentation is headache and contralateral hemiplegia
occurring in apatientwithahistoryofrecentHZophthalmicus,
although a variety of other stroke syndromes have been re-
ported. The mean interval fromacuteHZtoonsetofneurologic
symptoms in adults is ∼7 weeks, although intervals as long as
6 months have been reported. CSF examination reveals mono-
nuclear cell pleocytosis, and imaging studies (CT or MRI) show
changes consistent with brain infarction. Arteriography is usu-
ally diagnostic and demonstrates segmental inflammation,nar-
rowing, and thrombosis of the proximal branches of the middle
is 20%–25%, with a high probability of permanent neurologic
sequelae among survivors .
HZ myelitis is thought to result from direct in-
vasion of the spinal cord by VZV, with virus spreading along
central axons of infected primary sensory neurons. As in the
brain, close neuronal packing allows spread to adjacent neu-
rons. Involvement of descending spinothalamic tracts or of
anterior horn can cause weakness, and involvement of ascend-
ing sensory tracts (posterior column or lateral spinothalamic
tract) causes sensory loss at levelsbelowtheaffecteddermatome
. In severe cases, the myelopathy can progress to a partial
Brown-Se ´quard syndrome or total cord transection. Myelitis
most often follows thoracic HZ, with weakness developing in
the same spinal cord segment as the rash.Neurologicsymptoms
begin to develop an average of 12 days after the onset of the
rash . However, VZV myelitis in patients with no history
of antecedent HZ has also been reported [86, 87]. Immuno-
compromised patients are at increased risk for post-HZ mye-
litis, and the syndrome is well described in patients with AIDS
. The most common initial manifestation is bladder dys-
function (e.g., urinary retention), which is often accompanied
by weakness of the lower extremities, asymmetric reflexes, and
sensory disturbances . MRI has been useful in diagnosing
myelitis, with abnormal signal evident in the cord at the level
of inflammation . However, it should be noted that sub-
clinical MRI and CSF abnormalities have also been reported
. The prognosis for recovery of neurologic function is
Acute retinal necrosis caused by VZV has
been described in immunocompetent patients. More aggressive
variants of this disease have been recognized in patients with
AIDS and include VZV retinitis, progressive outer retinal
necrosis, and rapidly progressive herpetic retinal necrosis
(RPHRN) [90–92]. The RPHRN syndrome is seen almost ex-
clusively in patients with AIDS who have CD4+T cell counts
of !100 cells/mm3[92, 93]. This form of VZV retinitis may
occur concurrently with active HZ or, more frequently, may
develop weeks or months after the acute episode of HZ has
resolved. RPHRN can occur after HZ ophthalmicus or after
HZ involving a remote dermatome. The retinitis begins with
multifocal necrotizing lesions involving the peripheral retina.
Most patients present with unilateral involvement, but pro-
gression to bilateral disease occurs frequently [91, 92]. Fun-
doscopic examination reveals granular, yellowish, nonhemor-
rhagic lesions that rapidly extend and coalesce, often resulting
in retinal detachment. There is a relative lack of intraocular
inflammatory changes. RPHRN rapidly progresses to confluent
full-thickness retinal necrosis (which differs from the slow pro-
gression seen with CMV retinitis) and results in blindness in
75%–85% of involved eyes [92, 93]. The etiologic role of VZV
in most cases of RPHRN has been establishedbydemonstrating
VZV in choroid, vitreous fluid, and retinal biopsy specimens,
by means of culture or PCR . HSV occasionally causes an
identical syndrome [92, 94].
S10 • CID 2007:44 (Suppl 1) • Dworkin et al.
HZ rash heals but, rather, continues for months or years. This
persisting pain is termed PHN, and it is the most common
complication of HZ. Patients typically describe severaldifferent
types of pain, including continuous burning or throbbingpain,
intermittent sharp or electric shock–like pain, and allodynia
. Although multiple definitions of PHN have been used,
the results of recent studies suggest that pain persisting for at
least 120 days after rash onset may be considered to be a val-
idated definition of PHN for research purposes [96–98]. There
have been no systematic attempts to investigate the prevalence
of PHN, and estimates of the number of cases in the United
States have ranged up to 1 million . Numerous studieshave
established that older age is a potentrisk factorforPHN;greater
acute pain intensity, greater severity of the rash, and presence
and greater severity of a painful prodrome preceding the rash
are additional well-replicated risk factors [98, 100–103].
There is considerable agreement that both peripheral and
central processes contribute to PHN and that PHN is a het-
erogeneous disorder [104–106]. For example, patients with
prominent allodynia often have minimal sensory loss and re-
port pain relief after local application of analgesics, which sug-
gests that preserved, and possibly sensitized, primary afferent
nociceptors that remain connected to the skin and their chron-
ically sensitized central targets are responsible for initiatingand
maintaining pain and allodynia in these patients [105, 107].
Pathologic findings associated with PHN include degeneration
of affected primary afferent neuronal cell bodies and axons,
atrophy of the spinal cord dorsal horn, scarring of the dorsal
root ganglion, and loss of epidermal innervation, all of which
are more prominent on the affected side [44, 108–110].
Chronic pain has substantial effects on quality of life, and
physical disability and emotionaldistressarecommoninpatients
with PHN . The US Food and Drug Administration has
approved 3 medications for the treatment of PHN (gabapentin,
lidocaine patch 5%, and pregabalin), and the results of random-
ized controlled trials have also demonstrated the efficacy of tri-
cyclic antidepressants (TCAs) and opioid analgesics in treating
PHN [2, 3]. Nevertheless, a substantial percentage of patientsare
often refractory to thesetreatmentsusedaloneorincombination
 and require treatment in settings specializing in pain man-
agement. The results of controlled trials provide no basis for the
use of antiviral therapy in treating patients with PHN [112, 113],
although it has been suggested that higher dosages should be
studied in larger samples [114, 115].
Like pain, pruritis not infrequently per-
sists after HZ resolves . Postherpetic itch can occur along
with PHN or independently of it, which suggests different
mechanisms. Patients with chronic pruritis report substantial
disability, not only because of the unpleasant sensations but
also because of the disruptive need to scratch that is virtually
In some patients, pain does not resolve when the
impossible to ignore. The combination of chronic pruritis and
profound sensory loss after HZ leads to rare cases of severe
self-injury, when the protective pain sensations that deter pro-
longed scratching are lost . Pruritis associated with HZ is
neuropathic and does not respond to antihistamines or treat-
ments for inflammatory pruritis. There are no clinical trials,
but clinical experience suggests that postherpetic itch can be
resistant to most treatments that are efficacious for PHN but
can respond to those that suppress ectopic neuronal firing—
for example, local anesthetics.
METHODS USED FOR DEVELOPING
Data sources and study selection.
which the treatment recommendations were based was spon-
sored by the International Association for the Study of Pain
Neuropathic Pain Special Interest Group, the NeuropathicPain
Institute, and the VZV Research Foundation. Participants were
selected on the basis of research and clinical expertise relevant
to HZ and its management and represent the fields of anes-
thesiology, geriatrics, infectious diseases, internal medicine,
neurology, ophthalmology, outcomes research, pain manage-
ment, and virology. Relevant publications were identified by
Medline searches, examination of reference lists of published
articles and book chapters, and the personal knowledge of the
authors. Before the meeting, all participantswereprovidedcop-
ies of systematic literature reviews and meta-analyses [118–
121], existing guidelines relevant to the management of HZ
[122–125], and published randomized clinical trials, discussed
below. This literature and the authors’ clinical and research
experience were reviewed during the consensus meeting,which
was chaired by the first 2 authors. Information on additional
randomized trials that were not identified before the meeting
was provided on request after the meeting. Recommendations
for practice guidelines , best-evidence synthesis,and
narrative systematic reviews  were followed in developing
recommendations for the managementof HZandsummarizing
the literature on which they are based. The initial version of
the present article was prepared by the first 5 authors, revised
by the other authors, and recirculated until all authors agreed
with the text.
Recommendations for first-line pharmacologic treatments
are based on positive results from multiple randomized clinical
trials. The methods and results of these trials, in combination
with the clinical experience of the authors, provide the basis
for specific recommendations regarding these treatments. Be-
cause recommendations for first-line treatments are consistent
with the results of multiple trials and the clinical experience of
the authors, they are made with a high degree of confidence.
Recommendations for additional treatments that should be
considered in combination with first-line treatment are based
The consensus meeting on
Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S11
on the results of single clinical trials, inconsistent results of
multiple trials, or uncontrolled trials, considered together with
the clinical experience of the authors. These recommendations
are made with moderate confidence that these treatments
should be considered because they may provide additionalben-
efits when used in combination with first-line treatment.
Treatment effects on viral clearance,
acute pain, PHN (as reflected by the presence of either per-
sisting pain of any intensity or persisting pain of moderate or
greater intensity ), and other complications of HZ were
considered. In developing specific treatmentrecommendations,
these efficacy outcomes were considered together with safety
and tolerability as well as drug interactions, to evaluate the
overall risk-benefit ratio of treatment.
It was not possible to formally consider thecost-effectiveness
of treatment, because of limited data and differences related to
geographic region and third-party coverage. Clinicians should
familiarize themselves with medication acquisition costs and
the reimbursements provided by their patients’insuranceplans,
to protect their patients’ finances and encourage treatment
TREATMENT OF IMMUNOCOMPETENT
The principal goals of the treatment of HZ are reduction of
pain in immunocompetent patients and cessation of viral rep-
lication in immunocompromised patients and those with oph-
thalmic HZ. All patients should have a medical and psycho-
social history evaluation and targeted physical examination
performed to confirm the diagnosis, document comorbid ill-
nesses, and provide a basis for treatment. Prompt referral to
an ophthalmologist is required for all patients with ocular in-
volvement, whether immunocompetent or immunocompro-
mised. Elderly patients may be socially isolated, have cognitive
impairment or depression, or have had recent adverse major
life events (e.g., bereavement), all of which may impact treat-
ment compliance and response to treatment. Anxiety or de-
pression may also develop secondary to severe HZ, which may
further complicate treatment and disease resolution.
The treatment of HZ should occur in conjunction with ap-
propriate education and support from the health care provider.
Careful explanation of the disease, including the risk of viral
transmission to individuals who have not had chickenpox, and
of the proposed treatment plan is essential for adherence to
therapy and is beneficial to patient well-being; for example,
providing reassurance and education can dispelmythsandfears
about HZ and its implications for the patient’s health. En-
couragement, reassurance, and advice on quality of life are also
important and include supporting adequate nutrition and op-
timal levels of mental, physical, and social activity. Patients
should be told to keep the rash clean and dry to reduce the
risk of bacterial superinfection, to avoid use of topical anti-
biotics and of dressings with adhesive that can cause irritation
and delay rash healing, and to inform their physician if a sec-
ondary increase in temperature develops, which is often an
indication of bacterial infection. For some patients, discomfort
may be reduced by sterile wet dressings.
The efficacy of antiviral therapy in patients with HZ has been
demonstrated by multiple randomized controlled clinicaltrials.
Acyclovir (800 mg 5 times daily for 7–10 days), famciclovir
(500 mg 3 times daily for 7 days, the approved dosage inUnited
States; 250 mg 3 times daily is approved in some other coun-
tries), and valacyclovir (1000 mg 3 times daily for 7 days) have
been approved by the US Food and Drug Administration for
the treatment of HZ. These antiviral agents are phosphorylated
by viral thymidine kinase and cellular kinases to a triphosphate
form that inhibits viral replication.
Acyclovir was the first antiviral agent developed to treat HZ,
and 4 clinical trials examined the recommended oral dosage of
800 mg 5 times daily for 7–10 days beginning within 72 h of
rash onset [130–136]. Two clinical trials were conducted in
which various dosages of famciclovirwerecomparedwitheither
acyclovir  or placebo [138,139]. Asinglepublishedclinical
trial of 2 dosages of valacyclovir compared with acyclovir in
patients ?50 years of age  was accompanied by an un-
published trial of valacyclovir compared with placebo in pa-
tients !50 years of age. In addition, 2 trials in which famciclovir
and valacyclovir were compared with acyclovir [141, 142] and
1 trial examining various dosages of famciclovir comparedwith
acyclovir  were conducted in patients with HZ who were
followed for only 1 month from rash onset.
VZV replication is also inhibited by brivudin, an antiviral
agent that has been compared with acyclovir in 2 clinical trials
[144, 145] and with famciclovir in a recent large trial .
Brivudin (125 mg once daily for 7 days) has been approved
for the treatment of HZ in several countries.
These clinical trials demonstrated that orally administered
acyclovir, brivudin, famciclovir, or valacyclovir reduces the du-
ration of viral shedding and new lesion formation and accel-
erates rash healing in patients with HZ. In general, these agents
decrease the severity and duration of acute pain, and it is there-
fore also likely that antiviral therapy reduces the adverseimpact
of the acute phase of HZ on quality of life.
The effect of antiviral therapy on the development of PHN
has attracted particular attention because of the clinical im-
portance of preventing chronic pain. By inhibiting viral rep-
lication, antiviral therapy likely reduces neural damage, which
is thought to contribute prominently to the development of
S12 • CID 2007:44 (Suppl 1) • Dworkin et al.
PHN. For this reason, the delay in instituting antiviral therapy
should be as short as possible, to limitadditionalneuraldamage
beyond what may have occurred before rash onset.
The results of meta-analyses [119, 120, 147] and many [133,
135–140, 145, 146], but not all [130, 131, 134], randomized
controlled trials have demonstrated that antiviral therapy for
HZ significantly reduces the duration or incidenceofprolonged
pain. For example, in controlled trials using the recommended
dosages, the median time to complete loss of pain in patients
with pain at rash healing was 63 days with famciclovir, versus
119 days with placebo ; the median time to complete
cessation of pain was 38 days for valacyclovir, versus 51 days
for acyclovir . Although the effect of acyclovir on chronic
pain has been less clear because of negative results from some
trials [131, 148], the results of 2 meta-analyses suggest that it
may be superior to placebo in reducing the overall duration of
pain and the incidence of PHN [119, 120].
Although the results of each of the antiviral clinical trials
taken singly can be challenged, the preponderance of the find-
ings provides strong support for the use of antiviral therapy
not only to hasten resolution of the acute phase but also to
attenuate the development of chronic pain in patients with HZ.
Acyclovir, famciclovir, and valacyclovir are well tolerated and
safe . However,brivudin(whichisnotavailableintheUnited
States) must not be used to treat patients receiving 5-fluoro-
uracil (or other 5-fluoropyrimidines), because its main metab-
olite inhibits catabolism of fluorinated pyrimidine derivatives.
This drug interaction can causesevereandpotentiallyfatalbone
marrow suppression. The most common adverse effects asso-
ciated with antiviral therapy are nausea (occasionallywithvom-
iting) and headache, which occur in no more than 10%–20%
of patients, a rate generally similar to that found in patients
treated with placebo [138, 140, 144].
In head-to-head comparisons of effects on cutaneous and
pain end points, no differences were found betweenfamciclovir
and valacyclovir  and brivudin and famciclovir .
Some evidence suggests that these 3 agents may be somewhat
superior to acyclovir in reducing the likelihood of prolonged
pain[137, 140,145]. Inchoosingamongantiviralagents,factors
in addition to efficacy should be considered. Acyclovir, which
is available in generic forms, is less expensive than the antiviral
agents still protected by patent. However, dosing for brivudin
is once daily, and dosing for famciclovir and valacyclovir is 3
times daily, making these 3 antiviral agents considerably more
convenient than acyclovir, the optimal use of which requires
dosing every 5 h because of its pharmacokinetics.Furthermore,
when choosing an antiviral agent, it is also important to con-
sider the higher and more reliable levels of antiviral activity
achieved in blood with the use of oral brivudin, famciclovir,
or valacyclovir, compared with oral acyclovir. The existence of
barriers to the entry of antiviral agents from the bloodstream
into tissues that are sites of HZ complications and the lower
sensitivity of VZV compared with HSV make higher blood
levels of antiviral medications important.
All of the controlled clinical trials of antiviral therapy have
initiated treatment within 72 h of rash onset, an arbitrary in-
clusion criterion that does not necessarily reflect the cessation
of viral replication. Because patients often do not recognize the
significance of their symptoms or because there are delays in
scheduling their evaluation, HZ is often not diagnosed this
rapidly in clinical practice; obtaining medication can be an
additional delay. Thus, patients are often unable to initiate
treatment within this narrow window. Unfortunately, because
the efficacy of antiviral therapy initiated ?4 days after rash
onset has not been systematically studied, there is no evidence
base for such treatment. However, there is no difference in pain
outcomes when antiviral therapy is initiated before 48 h versus
48–72 h after rash onset , and the results of 2 uncontrolled
studies revealed no significant differences in the persistence of
pain between patients who initiated treatment within 72 h and
those who initiated treatment at a later time [151, 152]. Con-
a benefit from antiviral therapy initiated beyond 72 h after rash
A few studies have examined whether the benefit of antiviral
therapy is augmented when its duration is extended beyond 7
days [140, 153, 154]. The results of these studies suggest that
any benefit of extending treatment duration beyond 7 days may
be minimal, but this conclusion requires further investigation.
Recommendations for Antiviral Therapy
Topical antiviral therapy lacks efficacy in patients with HZ and
is not recommended. Systemic antiviral therapy is strongly rec-
ommended as first-line treatment for all immunocompetent
patients with HZ who fulfill any of the following criteria (see
table 1): (1) ?50 years of age; (2) have moderate or severe
pain; (3) have moderate or severe rash; or (4) have nontruncal
involvement. In patients who have a low risk for complications
of HZ—for example, those who are younger with mild acute
pain and rash and truncal involvement—the potential benefits
of treatment are unknown but may be meaningful becausesuch
patients can still develop PHN. Acyclovir, famciclovir, and val-
acyclovir are all exceptionally safe, which contributes to a fa-
vorable balance of potential benefit versus risk. It is, therefore,
recommended that antiviral therapy be considered even for
patients whose risk of developing PHNandothercomplications
of HZ is likely to be low.
There are no systematic data addressing the effectiveness of
antiviral therapy administered outside of the clinical trial set-
ting. Nevertheless, in clinical practice, brivudin, famciclovir,
and valacyclovir can be expected to have greater overall effec-
tiveness than acyclovir, on the basis of their potentiallysuperior
Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S13
Table 1. Oral antiviral medications for herpes zoster.
adverse effects Precautions and contraindications
Acyclovir 800 mg 5 times daily (every 4–5 h)7–10 Nausea, headache Dosage adjustment required for patients with renal
Contraindicated for patients treated with 5-fluoro-
uracil or other 5-fluoropyrimidines, because of
drug interaction associated with severe and
potentially fatal bone marrow suppression
Dosage adjustment required for patients with renal
125 mg once daily7 Nausea, headache
Famciclovir500 mg 3 times daily (approved
dosage in United States; in
some other countries, 250 mg 3
times daily is approved)
1000 mg 3 times daily
7 Nausea, headache
Valacyclovir7 Nausea, headache Dosage adjustment required for patients with renal
insufficiency; thrombotic thrombocytopenic
purpura/hemolytic uremic syndrome reported at
dosages of 8000 mg daily in immunocompro-
aNot available in the United States.
efficacy [137, 140, 145], the greater patient compliance asso-
ciated with their more convenient dosing, and their higher and
more reliable levels of antiviral activity in blood, which is im-
portant because of the existence of barriers to the entry of
antiviral agents from the bloodstream into tissues that are sites
of HZ complications.
In patients presenting 172 h after rash onset, the potential
benefits of initiating antiviral therapy are unknown but might
be meaningful, given the minimal risks of treatment with acy-
clovir, famciclovir, and valacyclovir. The presence of new ves-
icles or complications of HZ may identify patients with con-
tinuing viral replication who could benefit from treatment. It
is, therefore, recommended that the initiation of antiviral ther-
apy be considered for patients presenting 172 h after rash onset
with continued new vesicle formation or when there are cu-
taneous, motor, neurologic, or ocular complications.Advanced
age and severe pain (which are potent risk factors for PHN)
are additional factors that can prompt consideration of initi-
ating antiviral therapy 172 h after rash onset.
In patients who still have new vesicles forming or who have
cutaneous, motor, neurologic, or ocular complications after 7
days of antiviral therapy, close monitoring is recommended to
assess the need for further evaluation. Because the potential
benefits are unknown but may be meaningful, and given the
minimal risks of treatment, it is also recommended that con-
sideration be given to extending the duration of antiviral ther-
apy for 17 days for these patients. In patients who have been
given an incorrect diagnosis or who develop toxicity, antiviral
therapy should be discontinued immediately.
When rash healing has not occurred in a normal fashion in
an immunocompetent patient with HZ, further evaluation by
an infectious diseases specialist is recommended. Infectionwith
VZV resistant to acyclovir (mediated by absent or altered ex-
pression of thymidine kinase) has been reported in immuno-
compromised but not in immunocompetent patients.
Supplementing Antiviral Therapy
Although the reduction in chronic pain demonstrated by most
antiviral trials is both statistically and clinically significant, an-
tiviral therapy does not prevent PHN in all patients. In antiviral
trials, ∼20% of patients 150 years of age continue to have pain
6 months after their rash, despite treatment beginning within
72 h of rash onset [119, 139, 140, 149]. Although it is possible
that new antivirals with greater efficacy will be developed, a
different strategy for preventing PHN is to supplementantiviral
Two well-designed clinicaltrialsdem-
onstrated that the addition of a 3-week tapering dosage of a
corticosteroid did not contribute significantly, beyond the ben-
efits achieved by acyclovir alone, in reducing prolonged pain
[148, 153]. However, the addition of the corticosteroiddidhave
beneficial effects on acute pain and some cutaneous end points
in both of these trials; in one of the trials, the times to unin-
terrupted sleep, return to normal daily activity, and cessation
of analgesic therapy were all significantly accelerated inpatients
who received combination therapy . Individuals withcon-
traindications to the use of corticosteroids, including hyper-
tension, diabetes, and peptic ulcer disease, were excluded from
these studies. Nevertheless, adverse effects of corticosteroids
were reported, including gastrointestinal symptoms, edema,
No randomized placebo-controlled
trials of oral treatments for acute pain in patients with HZ have
S14 • CID 2007:44 (Suppl 1) • Dworkin et al.
been published. However,thewell-replicatedfindingthatmore-
severe acute pain is a risk factor for PHN, as well as research
on the pathophysiologic mechanisms of PHN, provide thebasis
for hypothesizing that the combinationofantiviraltherapywith
effective relief of acute pain may further lessen the risk of PHN
beyond that achieved with antiviral therapy alone . TCAs
have well-established efficacy in the treatment of PHN and
other neuropathic pain syndromes [156, 157], and TCAs may,
therefore, have an analgesic effect in HZ. The results of a pla-
cebo-controlled trial of amitriptyline (25 mg once daily for 3
months beginning within 48 h of rash onset) and a reanalysis
examining the subgroup of patients also treated with an an-
tiviral suggested that amitriptyline reduced the incidence of
PHN at 6 months by at least 50% [158, 159].
The effect of amitriptyline on acute pain was not assessed
in this study, and because treatment continued for 3 months
after rash onset, it cannot be determined whether the reduction
in PHN incidence was the result of early treatment. Amitrip-
tyline and other TCAs have generally poor tolerability and a
potential for serious adverse effects, including sudden cardiac
death [160, 161]. A screening electrocardiogram is recom-
mended to assess cardiac conduction abnormalities before be-
ginning TCA treatment of patients 140 years of age who have
neuropathic pain . Two selective serotonin and norepi-
better tolerated than TCAs and have recently been demon-
strated to have efficacy in patients withdiabeticpolyneuropathy
[163, 164]. However, until the efficacy of these antidepressants
is demonstrated for patients with PHN, there is little basis for
predicting that they would prevent its development when used
in patients with HZ.
Opioid analgesics would be expected to reduce acute pain
in patients with HZ because of their diverse mechanisms of
action in the peripheral nervous system and CNS as well as
their demonstrated efficacy in patients with both inflammatory
and neuropathic pain [165, 166], including PHN [167, 168].
Opioid analgesics are often used in combination with weak
analgesics, such as acetaminophen and nonsteroidal anti-in-
flammatory drugs (NSAIDs), but the efficacy of such combi-
nations has not been systematically studied in patients with HZ
or chronic neuropathic pain. Preliminary analyses of a recent
randomized trial showed that controlled-releaseoxycodonewas
superior to placebo in relieving acute pain in patients with HZ
within the first 2–3 weeks after rash onset, but the sample size
precluded an evaluation of the effect of treatment on PHN
. Tramadol, a weak m-opioid agonist that also inhibits the
reuptake of norepinephrine and serotonin, is efficacious in pa-
tients with PHN  but has not been studied as a treatment
Gabapentin and pregabalin act at the a2-d subunitofvoltage-
gated calcium channels to reduce neurotransmitter release,and
multiple studies have demonstrated their efficacy in patients
with chronic neuropathic pain , including PHN [171–
176]. The US Food and Drug Administration has approved
gabapentin for the treatment of PHN and pregabalin for the
treatment of PHN and painful diabetic polyneuropathy. The
combination of their generally satisfactory tolerability, safety,
and lack of drug interactions distinguish them from other oral
medications used in the treatment of neuropathicpain.Arecent
proof-of-concept study has demonstrated analgesic effects of a
single 900-mg dose of gabapentin versus placebo in patients
during the acute phase of HZ , and it has also been re-
ported that open-label treatment of a sample of 64 patients
with HZ, by use of the combination of gabapentin and the
antiviral agent valacyclovir, appeared to reduce the incidence
of PHN at 3 and 6 months after rash onset, compared with
the results of published studies of antiviral monotherapy.
Further evidence that these medications have the potential to
reduce acute pain in HZ is provided by the results of studies
of acute postoperative pain, in which perioperative adminis-
tration of gabapentin, compared with placebo, reduced pain or
opioid requirements .
Considered together, the efficacy of gabapentin and prega-
balin for the treatment of PHN and other chronic neuropathic
pain syndromes, the beneficial effects of gabapentinona variety
of acute pain conditions, and recent animal model data ,
suggest that these medications might reduce acute pain in pa-
tients with HZ and possibly further reduce the risk of PHN
beyond that achieved with antiviral therapyadministeredalone.
However, in preliminary data analyses from a randomized trial
, gabapentin titrated to a maximum dosage of 1800 mg
daily did not differ from placebo in reducing acute pain in HZ
within the first 2–3 weeks after rash onset. This may suggest
that dosages of gabapentin higher than the 1800 mg admin-
istered daily in this study are necessary for treatment of HZ or
that treatment with pregabalin would be preferable because it
can be titrated to an effective dosage more rapidly than ga-
bapentin , which is an important consideration when
treating patients whose acute pain can begin suddenly and can
often be severe. Although both gabapentin and pregabalin are
used in the treatment of epilepsy, other anticonvulsant medi-
cations are not recommended for patients with HZ, because of
their lack of proven efficacy in PHN, poor tolerability, or risks
of clinically significant adverse events.
Sympathetic and epidural nerve blocks
have been used for the treatment of severe pain in patients
with HZ for many years, but few controlled studies have ex-
amined their effects on acute pain or PHN [182–184]. The
results of a recent randomized trial involving patients with HZ
treated with oral antiviral therapy demonstrated that a single
epidural injection of steroids andlocalanestheticsrelievedacute
pain within the first month after rash onset significantly better
Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S15
than did the standard of care but did not reduce the risk of
developing PHN . Treatment with multiple epidural in-
jections of local anesthetic and methylprednisolone without
antiviral therapy during HZ was associated with a reduction in
the incidence of PHN, compared with that associated with
intravenous acyclovir and prednisolone . Given the well-
established efficacy of antiviral therapy in patients with HZ,
however, the results of this study have limited clinicalrelevance,
because antiviral therapy was withheld from the patients who
received epidural injections. Continuous epidural infusion of
local anesthetic with intermittent additional epiduralanesthetic
boluses was superior to continuous infusion of saline and in-
termittent anesthetic boluses in reducing the time to complete
cessation of pain in patients with HZ treated with acyclovir
. Although treatment of patients with HZ by use of mul-
tiple epidural injections or continuous epidural infusions is
unlikely to be feasible in most settings, these data suggest that
aggressive analgesia can be efficacious in patients with HZ.
A trial of intravenous VZV hyperim-
mune globulin versus placebo in patients 150 years of age with
a dermatologic diagnosis of HZ treated with intravenous acy-
clovir found a reduction in the incidence of pain 5 weeks after
rash onset; however, the effect of treatment on chronic pain
could not be determined because of the short follow-up du-
ration . Percutaneous electrical nerve stimulation admin-
istered 3 times each week for 2 weeks in patients with HZ was
superior to famciclovir for some but not all cutaneous and
acute pain end points, and for PHN severity but not incidence
, but the absence of adequate blinding in this study limits
interpretation of the data. Although topical capsaicin may have
benefit in some patients with PHN , there is no basis for
its use in patients with HZ, in whom it can be expected to
Recommendations for Supplementing Antiviral Therapy
Even if the risk of developing PHN is notreducedbycombining
antiviral therapy with analgesic or corticosteroid treatment in
patients with HZ, effective relief of acute pain is a verydesirable
treatment goal. Pain should be assessed and treated promptly,
and the choice of treatment approaches depends on the pa-
tient’s pain severity and underlying conditionsandonanyprior
response to specific medications. The principles of state-of-the-
art pain management, such as the use of standardized pain
measures, scheduled analgesia, and consistent and frequentfol-
low-up to adjust dosing to the needs of the patient, should be
applied to the management of pain in patients with HZ. It is
important to recognize that HZ pain changes over time and
can become more severe as the acute infection progresses.
Patients with mild to moderate pain may be managed with
acetaminophen or NSAIDs, alone or in combination with a
weak opioid analgesic (e.g., codeine) or tramadol. It is impor-
tant to prescribe these medications to achieve a constant level
of analgesia (e.g., every 6 h) rather than to use as-neededdosing
for increased levels of pain. These commonly usedmedications,
however, have not been studied for the treatment of HZ. For
pain that is moderate to severe in intensity, which is often
accompanied by disturbed sleep, treatmentwith astrongopioid
analgesic (e.g., oxycodone or morphine) is recommended on
the basis of the consistent efficacy of this class of medications
in patients with inflammatory and neuropathic pain (table 2).
Various approaches may be used to treat HZ-associated pain
with the numerous short- and long-acting opioid analgesics
that are available. One approach is to begin treatment with a
short-acting medication at an oxycodone equianalgesic dosage
of 5 mg given 4 times daily as needed. Commonly used short-
acting opioid analgesics include oxycodone alone or in com-
bination with acetaminophen or aspirin. Once an effective
dosage is determined, treatment can be switched from a short-
acting to a long-acting medication, which is more convenient
for patients and may also provide a more consistent level of
pain relief; for exacerbations of pain, treatment with a short-
acting opioid can be continued on an as-needed basis, in com-
bination with the long-acting opioid. One of the most common
adverse effects of opioid analgesics is constipation, which can
be managed with preemptive laxative and stool-softener ther-
apy. The risk that substance abuse will develop in patients who
do not have a history of substance abuse is unknown, but is
thought to be low in older individuals with HZ.
If moderate to severe pain in patients with HZ has not re-
sponded rapidly to treatment with an opioid analgesic, the
prompt addition of one of the following 3 classes of oral med-
ications in combination with the opioid analgesic should be
considered, even though few studies have examined whether
the risk of PHN is reduced by such treatment: (1) gabapentin
or pregabalin; (2) TCAs, especially nortriptyline; or (3) corti-
costeroids (e.g., prednisone), if there are no contraindications
(table 2). For those patients with moderate or severe pain who
are unable to tolerate an opioid analgesic, treatment with these
3 classes of medications, alone and in combination, can be
Gabapentin and pregabalin can both cause sedation, and
tolerability may be improved with initial doses given only at
bedtime and subsequent dosage increases administered 3 times
daily for gabapentin and twice daily for pregabalin. The first 2
weeks after rash onset can be expected to be associated with
the greatest benefit of treatment. Aggressive titration to rapidly
reach the maximum dosages of 3600 mg of gabapentin daily
and 600 mg of pregabalin daily must be balanced against the
risk of greater adverse effects. Final dosages of gabapentin and
pregabalin should be determined by relief of pain or the de-
velopment of unacceptable adverse effects that do not resolve
within 1 or 2 days.
Corticosteroid and analgesic medications that can be considered for treatment of patients with herpes zoster.
Most common adverse effects
Opioid analgesics (dosages given
are for oxycodone)a
5 mg every 4 h as needed; dosage can
be converted to long-acting opioid
analgesic combined with short-acting
medication continued as needed
Increase by 5 mg 4 times daily
every 2 days as tolerated
No maximum dosage with careful
titration; consider evaluation by a
pain specialist at dosages 1120
50 mg once or twice daily
Increase by 50–100 mg daily
in divided doses every 2
days as tolerated
400 mg daily (100 mg 4 times daily);
for patients 175 years of age, 300
mg daily in divided doses
sedation, dizziness, seizures,
300 mg at bedtime or 100–300 mg 3
Increase by 100–300 mg 3
times daily every 2 days astolerated
3600 mg daily (1200 mg 3 times
daily); reduce if renal function is
Sedation, dizziness, peripheral edema
75 mg at bedtime or 75 mg twice daily Increase by 75 mg twice daily
every 3 days as tolerated
600 mg daily (300 mg twice daily);
reduce if renal function is
Sedation, dizziness, peripheral edema
25 mg at bedtime
Increase by 25 mg daily every
2–3 days as tolerated
150 mg daily
Sedation, dry mouth, blurred vision,
weight gain, urinary retentionc
Oral corticosteroid (dosages given
60 mg daily for 7 days
After 60 mg daily for 7 days,
decrease to 30 mg daily for 7 days, then decrease to 15
mg daily for 7 days, and
60 mg daily
Gastrointestinal distress, nausea,
changes in mood, edema
aConsider lower starting dosages and slower titration for frail and elderly patients (e.g., 5 mg twice daily for oxycodone); dosages given are for short-acting formulations.
bConsider lower starting dosages and slower titration for frail and elderly patients (e.g., 10 mg at bedtime for tricyclic antidepressants).
cConsider a screening electrocardiogram for patients ?40 years of age.
dShould be initiated only in combination with antiviral therapy.
Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S17
Although most clinical trials of TCAs for the treatment of
neuropathic pain have examined amitriptyline, it is not rec-
ommended for elderly patients, because of theriskofsignificant
adverse events. In a randomized double-blind trial, nortrip-
tyline was found to provide equivalent analgesic benefits for
patients with PHN, when directly compared with amitriptyline,
but was better tolerated . Nortriptyline is, therefore, pref-
erable, although desipramine can be considered for patients
with excessive sedation from nortriptyline. Nortriptyline treat-
ment can be initiated at a dosage of 25 mg (or less for frail or
elderly patients) at bedtime and then titrated by 25 mg daily
every 2–3 days as tolerated, until relief of pain or a maximum
dosage of 150 mg daily is reached. Patients must understand
that TCAs have an analgesic effect that is independent of their
Corticosteroids can be considered as soon as possible after
diagnosis for patients with at least moderately severe pain and
no contraindications. In addition, corticosteroids should be
considered for patients with VZV-induced facial paralysis and
cranial polyneuritis to improve motor outcomes, peripheral
nerve damage from foraminal compression, orevidenceofCNS
involvement, although the benefit of such treatment has not
been systematically studied. Contraindications (e.g., hyperten-
sion, diabetes, gastritis, osteoporosis, and psychosis) and risks
associated with the use of corticosteroids must be carefully
evaluated. Treatment with corticosteroids should be initiated
only in combination with antiviraltherapy.Thereisnoevidence
base for the use of topical corticosteroids for treatment of pa-
tients with HZ, and such treatment is not recommended.
For patients with pain that is inadequately controlled by
antiviral agents in combination with oral analgesic medications
and/or corticosteroids, referral toapainspecialistorpaincenter
is recommended to evaluate eligibility for neural blockade. Al-
though long-term benefits of neural blockade in HZ have not
been established, these procedures can reducesevereacutepain,
and their risk-benefit ratio is therefore likely to be favorable.
Patients with the most severe lesions and pain may benefitfrom
hospitalization and administration of epidural analgesics.
TREATMENT OF IMMUNOCOMPROMISED
Patients with disorders of cell-mediated immunity (due to dis-
ease or medical interventions) are at increased risk for devel-
opment of HZ. Those patients with the greatest degree of im-
munosuppression are at highest risk for VZV dissemination
and visceral organ involvement. Populations at special risk in-
clude patients with lymphoproliferative malignancies, organ
transplant recipients, patients receiving systemic corticoste-
roids, and patients with AIDS.
HZ in the setting of malignancy or organ transplantation.
Initial clinical trials with intravenous acyclovir for localized or
disseminated HZ in immunocompromised patients demon-
strated that treatment halts disease progression and reduces the
duration of viral replication [193, 194]. Subsequent studies of
bone marrow transplant recipients proved that acyclovir, in
addition to promoting faster disease resolution, is highly ef-
fective at preventing VZV dissemination [195, 196]. Because
most VZV-related fatalities result from disseminated infection,
the ability to prevent dissemination has markedly reduced the
rate of death due to HZ in transplant recipients.
Intravenous acyclovir remains the therapy of choice for VZV
disease in severely immunocompromised patients, including
(1) allogeneic hematopoietic stem cell transplant recipients
within 4 months of transplantation, (2) hematopoietic stem
cell transplant recipients with moderate to severe acute or
receiving aggressive antirejection therapy. In addition, any
transplant recipient with suspected visceral dissemination(e.g.,
encephalitis or pneumonitis) should receive intravenous acy-
clovir. The recommended dose is 10 mg/kg (or 500 mg/m2)
every 8 h. When the infection is controlled, intravenous ad-
ministration can be stopped, and oral antiviral medication can
be initiated for the remainder of the course of therapy.
For immunocompromised patients, treating HZ with oral
antiviral agents on an outpatient basis is an attractiveapproach,
although data are limited. One small study randomized 27 al-
logeneic hematopoietic stem cell transplant recipients with HZ
to receive either oral or intravenous acyclovir. No VZV dis-
semination occurred in either group, and no differences in
healing or clinical outcome wereapparent.Publisheddata
from clinical trials of famciclovir and valacyclovir for the treat-
ment of HZ in immunocompromised patients remain limited,
but a growing body of clinical experience suggests that these
medications are safe and effective in this setting [198, 199]. For
less severely immunosuppressed patients, oraltherapywithacy-
clovir (800 mg 5 times daily), valacyclovir (1000 mg 3 times
daily), or famciclovir (500 mg 3 times daily), coupled with
close clinical observation, is a reasonable option. The higher
plasma drug concentrations achievable with famciclovir and
valacyclovir, along with their simplified dosing schedule, favor
the use of these medications rather thanoralacyclovir.Brivudin
is not recommended for immunocompromised patients, even
though it is effective , because of its potentially fatal in-
teraction with 5-fluorouracil and other 5-fluoropyrimidines
used in cancer chemotherapy. Because of the risk of ocular
involvement, intravenous acyclovir and evaluation by an oph-
thalmologist is recommended for highly immunocompromised
patients who present with HZ ophthalmicus .
HZ in HIV-seropositive patients.
data to guide clinicians when selecting antiviral therapy for HZ
in HIV-seropositive patients are currently limited. Nearly 300
HIV-infected patientswith HZwereenrolledincontrolledstud-
S18 • CID 2007:44 (Suppl 1) • Dworkin et al.
ies comparing orally administered acyclovir (800 mg 5 times
daily) with sorivudine (40 mg once daily) [202, 203]. Times to
cessation of new vesicle formation, total crusting, and resolu-
tion of HZ-associated pain were 3–4 days, 7–8 days, and ∼60
days, respectively . Although sorivudine was never mar-
keted, these studies clearly confirmed the efficacy and safety of
oral antiviral therapy for HZ in patients with HIV infection.
Famciclovir was judged to be effective and safe for treatment
of HZ in patients with AIDS when evaluated in a small, open-
label clinical trial . Valacyclovirhasnotbeensystematically
evaluated as a treatment for HZ in HIV-infected patients, al-
suggest therapeutic benefit. Patients who have HZ ophthal-
micus should always be treated to reduce the risk of serious
ocular complications, even when presenting 172 h after rash
onset [205, 206]. Because of the documented risk of relapsing
infection, VZV disease in HIV-seropositive patients should be
treated until all lesions have healed, which is often longer than
the standard 7- to 10-day course. What impact VZV therapy
may have on the risk of subsequent complications, such asCNS
infection or retinitis, is unknown. Adjunctive therapy for HZ
with corticosteroids has not been evaluated in HIV-infected
patients and is not currently recommended. Long-term ad-
ministration of anti-VZV medications to prevent recurrences
of HZ is not routinely recommended for HIV-infectedpatients.
Although rare, acyclovir-resistant VZV has been reported in
immunocompromised patients, especially those with HIV in-
fection, and results from mutations in the thymidine kinase
gene. The presence of atypical lesions or a failed clinical re-
sponse should prompt evaluation for drug susceptibility to de-
termine whether resistance has developed. When acyclovir re-
sistance occurs, treatment with alternative medications (e.g.,
intravenous foscarnet or cidofovir) is required.
Management of acute pain in HZ and PHN is similar in
immunocompromised and immunocompetent patients, al-
though NSAIDs that are not cyclooxygenase II–specific inhib-
itors are contraindicated in thrombocytopenic patients.
TREATMENT OF COMPLICATED
PRESENTATIONS OF HZ
HZ ophthalmicus and VZV retinitis.
second only to thoracic HZ in frequency . Two surveys
of all cases of HZ occurring between 1935 and 1959 in Roch-
ester, Minnesota, found a trigeminal HZ incidence of 9%–16%
[208, 209], which is within the 8%–56% range found in other
studies [32, 210, 211]; some of these estimates, however, may
have been biased by a greater tendency for patients with facial
or periocular rashes to seek medical attention. A trigeminalHZ
incidence of ∼10.7% was found for the 660 evaluable cases of
HZin theplacebo groupoftheShinglesPreventionStudy.
Without antiviral therapy, 50%–72% of patientswithperiocular
HZ ophthalmicus is
HZ will have involvement of the ocular structures and develop
chronic disease; in one recent study, 20% of patients with HZ
uveitis were found to be legally blind in the involved eye .
The list of complications is protean: scarred lid malfunction
or loss; paralytic ptosis; conjunctivitis; episcleritis; scleritis; in-
fectious or neurotrophic keratitis; iridocyclitis; hemorrhagic
retinitis; acute retinal necrosis; choroiditis; papillitis; retrobul-
bar neuritis; optic atrophy; Argyll Robertson pupil; partial or
complete third, fourth, or sixth nerve palsy (always self-re-
solving); isolated pupillary paralysis; internuclear ophthalmo-
plegia; acute and chronic glaucoma; orbital apex syndrome;
PHN; and sympathetic ophthalmia [210, 214–218].
Therapy for HZ ophthalmicus is similar to that for HZ else-
where in the body but should include the care of an ophthal-
mologist familiar with the disease. Treatment includes the fol-
lowing [217, 218]: (1) approved dosages of famciclovir or
valacyclovir for 7–10 days, preferably started within 72 h of
rash onset (with intravenous acyclovir given as needed for ret-
initis), to resolve acute disease and inhibit late inflammatory
recurrences [136, 219–222]; (2) pain medications, as discussed
above; (3) cool to tepid wet compresses (if tolerated); (4) an-
tibiotic ophthalmic ointment administered twice daily (e.g.,
bacitracin-polymyxin), to protect the ocular surface; (5) topical
steroids (e.g., 0.125%–1% prednisolone 2–6 times daily) pre-
scribed and managed only by an ophthalmologist for corneal
immune disease, episcleritis, scleritis, or iritis; (6) no topical
antivirals, because they are ineffective;(7)mydriatic/cycloplegia
as needed for iritis (e.g., 5% homatropine twice daily); and (8)
ocular pressure–lowering drugs given as needed for glaucoma
(e.g., latanaprost once daily and/or timolol maleate ophthalmic
gel forming solution every morning). Systemic steroids are in-
dicated in the presence of moderate to severe pain or rash,
particularly if there is significant edema, which may cause or-
bital apex syndrome through pressure on the nerves entering
the orbit . The dosage is commonly 20 mg of prednisone
administered (together with an oral antiviral agent) orally 3
times daily for 4 days, twice daily for 6 days, and then once
daily every morning for 4 days.
Therapy for chronic problems includes the following: (1)
lubricating, preservative-free artificial tear gels or tears admin-
istered 4 times daily, antibiotic ointment administered once
daily, and, possibly, lateral tarsorrhaphy to protect the corneas
(which are often hypesthetic/anesthetic as a result of neuronal
damage) from breakdown; (2) continuous-wear, therapeutic
soft contact lenses and antibiotic drops (e.g., polymyxin-tri-
methoprim given 4 times daily as needed for corneal ulcera-
tion); (3) topical steroids and antibiotics for inflammatory dis-
ease (iritis, episcleritis, scleritis, and immune keratitis); (4)
dilation for iritis; (5) glaucoma therapy as needed; and (6)
surgical management as needed—for example, for amniotic
membrane transplantation, tissue-adhesive seal ulcers, kera-
Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S19
toprosthesis, and glaucoma trabeculectomy. Chronicpainman-
agement is generally similar to that for PHN in other der-
matomes and includes gabapentin or pregabalin, TCAs, opioid
patch for periophthalmic use). Local nerve blocks or sympa-
thetic blocks can be used for pain that is refractory to first-
line therapy, although there are no controlled studies of these
The optimal antiviral therapy for VZV-induced, rapidly pro-
gressive herpetic retinal necrosis in immunocompromised pa-
tients remains undefined. Responses to intravenous acyclovir
or ganciclovir have been inconsistent and disappointing, with
49%–67% of involved eyes progressing to no light perception
[91, 226]. Several case reports have reported improved pres-
ervation of vision in patients treated with a combination of
intravenous ganciclovir plus foscarnet, with or without intra-
vitreal antivirals [227–232]. Cidofovir has also been used suc-
cessfully in a small number of patients [233, 234]. The optimal
duration of induction therapy and options for long-termmain-
tenance therapy have not been established.
Acute retinal necrosis in immunocompetent patients is a less
virulent disease and responds better to antiviral therapy. For
such patients, acyclovir is clearly beneficialforpreservinguseful
vision . A suggested antiviral regimen for acute retinal
necrosis in the otherwise healthy host is intravenous acyclovir
(10–15 mg/kg every 8 h for 10–14 days) followed by oral val-
acyclovir (1 g 3 times daily for 4–6 weeks), although this treat-
ment approach has not been studied in a controlled fashion.
Vulnerable and frail elderly patients.
older adults varies widely, from well elderly individuals who
have no diseases or functional problemstochronicallyillelderly
individuals who have multiple comorbidities and disabilities.
Vulnerable elderly individuals are people ?65 years of age who
are at increased risk for death or functional decline in a 2-year
period, as defined by older age, poor self-rated health, and
decreased functional status . Frail elderly individuals, a
subset of vulnerable elderly individuals, are at the highest risk
for death and functional decline and are characterizedclinically
by weakness, easy exhaustion, low levels of physical activity,
slow walking speed, undernutrition/weight loss, and functional
decline . Importantly, functional status is a more impor-
tant predictor of death and functional decline than are specific
clinical conditions. These individuals have markedly dimin-
ished physiologic reserves for responding to stressors,including
such acute illnesses as HZ. Cutaneous dissemination and, pos-
sibly, visceral dissemination seem to be more common in el-
derly individuals. Moreover, the pain and acute inflammation
of HZ puts vulnerable and frail elderly individuals at risk for
physical inactivity, poor oral intake with resultant undernutri-
tion, cognitive impairment, depression, and functional decline.
The insult of HZ can trigger a change of living environment
The health status of
in a frail elderly individual who is living alone and experiences
Hence, when HZ occurs in this population, it is important
to modify pharmacotherapeutic approaches and augment non-
ages of medications should be lower than those recommended
for younger individuals, and the dosage should be titratedmore
slowly, particularly for opioid analgesics, gabapentin, prega-
balin, TCAs, and NSAIDs. These individuals experience sig-
nificant age- and disease-related declines in glomerular filtra-
tion rate, so the dosages of renally excreted medications (e.g.,
antiviral agents, gabapentin, and pregabalin) must be adjusted,
as is discussed further below . Furthermore, these indi-
viduals are at high risk for adverse drug effects because of
multiple comorbidities, age-related changes in pharmacoki-
netics and dynamics, use of multiple medications, and frequent
inappropriate prescribing . The choice of medications
should take into account the patient’s diseases, medicationreg-
imen, and adverse event experiences. For example, NSAIDs
should be avoided in elderly individuals with congestive heart
failure and chronic kidney disease. For nonpharmacotherapeu-
tic approaches, it is critically important for the practitioner to
recognize that these treatments are just as important as the use
of medications. Nonpharmacologic approaches include main-
taining physical activity, enhancing nutrition, maintaining or
increasing social contact, and providing assistance forproblems
with basic and instrumental activities of daily living during the
acute episode. These interventions usually require a multidis-
ciplinary approach that involves nursing, social work, physical
therapy, occupational therapy, and the family.
The clinical course of vulnerable and frail elderly individuals
needs to be monitored more closely than does that of wellelderly
individuals, to detect inadequate responses to therapy and early
functional decline and to step up interventions, if needed. Phar-
inflammation may worsen cognition in these individuals with
dementia, who then may require additional assistance in ob-
taining proper treatment and performing activities of daily liv-
ing. The management of HZ pain is more complicated in pa-
tients with dementia, because of the risk for adverse cognitive
effects of opioid analgesics, gabapentin, pregabalin, and TCAs.
In addition, traditional pain measures (e.g., the 0–10 numerical
rating scale) used to track response to analgesics are not useful
in assessing patients with advanced dementia . Finally,
when frail elderly individuals are residents of nursing homes,
prompt recognition and initiation of antiviral treatment of HZ
can prevent the spread of VZV to susceptible individuals, such
as younger nurses and aides in the facility .
Pregnant and nursing patients.
transmitted to the fetus and cause significant morbidity, but
Maternal varicella can be
S20 • CID 2007:44 (Suppl 1) • Dworkin et al.
congenital varicella has never been documented in association
with maternal HZ. There are no adequate studies of the effects
that antiviral therapy during pregnancy has on the developing
child, although rates of birth defects reported in registry data
for acyclovir and valacyclovir are reassuring (similar data are
not available for famciclovir and brivudin) . Because the
safety of antiviral therapy during pregnancy has not beenfirmly
established, pregnant women with HZ should be treated only
in cases in which the potential benefits of antiviral therapy to
the mother outweigh the potential risks to the fetus. The ma-
jority of pregnant women with HZ are expected to have a
relatively low risk of developing PHN, because of their age.
However, patients with severe rash, severe acute pain, or HZ
ophthalmicus can be treated with acyclovir and valacyclovir,
especially during the late stages of pregnancy, when any po-
tential risks to the fetus should be lower. However, during the
early stages of pregnancy, the potential benefit of antiviralther-
apy to the mother must be great enough to outweigh the un-
known but potentially greater risk to thefetus.Antiviraltherapy
is not routinely recommended for eclamptic, preeclamptic, or
diabetic pregnant women.
Because acyclovir is excreted in breast milk, antiviral therapy
should be administered to nursing mothers with caution and
only in circumstances in which the benefits are well established
(e.g., within 72 h of rash onset). Severe acute pain in pregnant
patients with HZ can be safely treated with opioid analgesics,
but this must then be considered in the management of the
Neurologic complications of HZ.
agents in the management of neurologic complications of HZ
has not been evaluated in a controlled fashion. For those dis-
eases in which viral replication likely plays an important role
in pathogenesis (e.g., meningitis, encephalitis, and myelitis),
therapy with intravenous acyclovir is recommended; this ap-
proach is supported by benefits noted in anecdotal experience.
For such conditions as delayed contralateral hemiparesis, in
which the role of active viral replication is less clear, the value
of antiviral therapy is uncertain, but the potential benefits of
antiviral therapy outweigh any potential risks .
Dosages should be adjusted if renal insuf-
ficiency is present when acyclovir (creatinine clearance, !25
mL/min), famciclovir (creatinine clearance, !60 mL/min), or
valacyclovir (creatinine clearance, !50 mL/min) is used. Be-
cause brivudin undergoes hepatic as well as renal excretion,
dosage reduction for renal insufficiency is less critical, but he-
patic function must be considered when this antiviral agent is
used. Dosages of gabapentin and pregabalin should be reduced
when renal function is impaired.
The role of antiviral
RECOMMENDATIONS FOR FUTURE RESEARCH
Major advances have been made in the prevention and treat-
ment of HZ and PHN. To further reduce the personal and
social burden of HZ, additional research on the natural history
of HZ is necessary and should include studies of the following:
(1) the impact of varicella and HZ vaccination on epidemio-
logical aspects of HZ and its complications; (2) the risk factors
for HZ and its complications—for example, the role of im-
munosenescence, nervous system senescence, greater HZ se-
verity, and medical comorbidity in explaining why older pa-
tients with HZ have a greater risk of developing PHN; (3)
methods for the early identification of HZ by patients and
health care providers, so that treatment is initiated as promptly
as possible in those who are at risk for the development of
complications; (4) methods for identifying HZ before the rash
appears and in patients with very mild rashes; (5) methods for
identifying patients with zoster sine herpete; (6) the mecha-
nisms of pain in HZ and PHN and of the transition from acute
pain to PHN; and (7) the role of VZV in neurologic and other
Additional research on the prevention and treatment of HZ
and on the prevention of its complications, especially PHN, is
also necessary and should include studies of the following: (1)
improved (e.g., lipophilic) antiviral therapy for HZ; (2) treat-
ments for acute pain in patients with HZ (e.g., to determine
whether NSAIDs are efficacious); (3) strategies topreventPHN,
ideally based on improved knowledge of pain mechanisms; (4)
novel strategies to block reactivation of VZV or to eliminate
latent infection within neurons; (5) research on extending the
use of the live attenuated HZ vaccine to frail elderlyindividuals,
immunocompromised patients, and individuals !60 years of
age; (6) the development of noninfectious (inactivated) HZ
vaccines for use in immunocompromised individuals; (7) the
development and evaluation of epitope-specific recombinant
DNA vaccines for HZ that would selectively stimulate VZV-
specific cell-mediated immune responses;(8)methodsforiden-
tifying which patients would benefit from antiviral therapy ini-
tiated 172 h after rash onset; and (9) methods for identifying
which patients would benefit from antiviral therapy extending
for 17 days. Both of the latter 2 objectives should be a priority
for research on HZ.
We anticipate that ongoing and planned researchwilladdress
these questions and that clinical trials will identify additional
treatments with efficacy in the prevention and treatment of HZ
and PHN, and we therefore recommend that these clinical rec-
ommendations be updated within 5 years.
We dedicate these recommendations to the memoryofRichardT.Perkin,
whose passion forsupportingresearchandeducationtoreducethesuffering
Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S21
caused by chickenpox, herpes zoster, and postherpetic neuralgia is an en-
during inspiration. We thank Paul Lambiase and Mary Gleichauf of the
University of Rochester Office of Professional Education for invaluable
The consensus meeting on which these recom-
mendations are based was supported by unrestricted grants to the Uni-
versity of Rochester Office of Professional EducationfromtheInternational
Association for the Study of Pain Neuropathic Pain Special Interest Group,
the Neuropathic Pain Institute, and the VZV Research Foundation.
This article was published as part of a sup-
plement entitled “Recommendations for the Management of Herpes Zos-
ter,” sponsored by the International Association for the Study of Pain
Neuropathic Pain Special Interest Group, the Neuropathic Pain Institute,
and the VZV Research Foundation.
Potential conflicts of interest. All authors received an honorarium for
participation in the consensus meeting from the University of Rochester
Office of Professional Education. R.H.D. has received research support,
consulting fees, or honoraria in the past year from Allergan, Astellas
Pharma, Cephalon, Dov Pharmaceuticals, Eli Lilly, Endo Pharmaceuticals,
EpiCept Corporation, Fralex Therapeutics, Johnson & Johnson, Merck,
NeurogesX (also stock options), Novartis,Pfizer,SchwarzPharma,USFood
and Drug Administration, US National Institutes of Health, and US Vet-
erans Administration; R.W.J. has received consulting or lecture fees from
DepoMed, Merck, Novartis, Sanofi Pasteur MSD, and Yamanouchi; J.B.
has served on advisory boards for GlaxoSmithKline, Merck, and Sanofi
Pasteur; J.W.G. has received research support, consulting fees, or honoraria
from Astellas Pharma, GlaxoSmithKline, Merck, and Novartis; M.J.L. has
received consulting fees from GlaxoSmithKline and Merck and shares a
patent with Merck for the herpes zoster vaccine; M.B. has received research
support, consulting fees, or honoraria in the past year from Allergan, As-
tellas Pharma, Cephalon, Eli Lilly, Eisai, Johnson & Johnson, Merck,
NeurogesX, Pfizer, Schwarz Pharma, and Xenoport; A.A.G. has received
consulting or lecture fees from GlaxoSmithKline and Merck; M.L.H. has
received consulting fees or honoraria in the past year from AstraZeneca,
Mundipharma MSD, and Pfizer; M.W.M has served on an advisory board
for Sanofi Pasteur MSD in the past year; T.J.N. has received research sup-
port, consulting fees, or honoraria in the past year from Eli Lilly, GW
Pharma, Medtronic, Merck, Pfizer, Schwarz BioSciences, andUCBPharma;
K.L.P. has received consulting fees or honoraria in the past year from CV
Therapeutics, Eli Lilly, Evotech, NeurogesX, Neuromed, Organon, and
Roche; M.C.R. has received consulting fees or royalties in the past 12
months from Alnylam, Biogen, Eli Lilly, Hind Health Care, Metaphore,
and NeuroMolecular; K.E.S. has received research support and consulting
fees from Merck; B.R.S. has received consulting fees or honoraria in the
past year from Pfizer, Lilly, and Depomed; S.K.T has received research
support, consulting fees, or honoraria from Astellas Pharma, Catalyst,
GlaxoSmithKline, Merck, and Novartis; A.J.M.vW. has received honoraria
from Pfizer and Sanofi Pasteur MSD; S.W.W. has received consulting fees
or honoraria in the past year from Berlin Chemie, GlaxoSmithKline, Men-
arini Group, Sanofi Pasteur MSD, and Stockhausen Degussa; M.S.W. has
received consulting fees from Endo Pharmaceuticals and honoraria from
Pfizer in the past year; R.J.W. is on the Scientific Advisory Board for Gilead
and the speakers bureaus for GlaxoSmithKline and Novartis. All other
authors: no conflicts.
1. Gnann JW Jr, Whitley RJ. Herpes zoster. N Engl J Med 2002;347:
2. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice
parameter: treatment of postherpetic neuralgia: an evidence-based
report of the Quality Standards Subcommittee of the American Acad-
emy of Neurology. Neurology 2004;63:959–65.
3. Hempenstall K, Nurmikko TJ, Johnson RW, A’Hern RP, Rice AS.
Analgesic therapy in postherpetic neuralgia: a quantitative systematic
review. PLoS Med 2005;2:e164.
4. Ku CC, Padilla JA, Grose C, Butcher EC, Arvin AM. Tropism of
varicella-zoster virus for human tonsillar CD4+T lymphocytes that
express activation, memory, and skin homing markers. J Virol 2002;
5. Ku CC, Besser J, Abendroth A, Grose C, Arvin AM. Varicella-Zoster
virus pathogenesis and immunobiology: new concepts emergingfrom
investigations with the SCIDhu mouse model.JVirol2005;79:2651–8.
6. Ku CC, ZerboniL, ItoH, GrahamBS,WallaceM,ArvinAM.Varicella-
zoster virus transfer to skin by T cells and modulation of viral rep-
lication by epidermal cell interferon-a. J Exp Med 2004;200:917–25.
7. Chen JJ, Gershon AA, Li ZS, Lungu O, Gershon MD. Latent and lytic
infection of isolated guinea pig enteric gangliabyvaricellazostervirus.
J Med Virol 2003;70(Suppl 1):S71–8.
8. Gershon AA, Sherman DL, Zhu Z, Gabel CA, Ambron RT, Gershon
MD. Intracellular transport of newly synthesised varicella-zoster vi-
rus: final envelopment in the trans-Golgi network. J Virol 1994;68:
9. Cole NL, Grose C. Membrane fusion mediated by herpesvirus gly-
coproteins: the paradigm of varicella-zoster virus. Rev Med Virol
10. Wang, ZH, Gershon MD, Lungu O, Zhu Z, Gershon AA. Trafficking
of varicella-zoster virus glycoprotein gI: T(338)-dependent retention
in the trans-Golgi network, secretion, and mannose 6-phosphate-
inhibitable uptake of the ectodomain. J Virol 2000;74:6600–13.
11. Dahms NM, Lobel P, Kornfeld S. Mannose 6-phosphate receptorsand
lysosomal enzyme targeting. J Biol Chem 1989;264:12115–8.
12. Westlund B, Dahms NM, Kornfeld S. The bovine mannose 6-phos-
phate/insulin-like growth factor II receptor: localization of mannose
6-phosphate binding sites to domains 1–3 and 7–11 of the extracy-
toplasmic region. J Biol Chem 1991;266:23233–9.
13. Chen JJ, Zhu Z, Gershon AA, Gershon MD. Mannose 6-phosphate
receptor dependence of varicella zoster virus infection in vitro and
in the epidermis during varicella and zoster. Cell 2004;119:915–26.
14. Lungu O, Annunziato PW, Gershon A, et al. Reactivated and latent
varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad
Sci U S A 1995;92:10980–4.
15. Cohrs RJ, Barbour M, Gilden DH. Varicella-zoster virus (VZV) tran-
scription during latency in human ganglia: detection of transcripts
mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for
VZV RNA. J Virol 1996;70:2789–96.
16. Kennedy PG, Grinfeld E, Bell JE. Varicella-zostervirusgeneexpression
in latently infected and explanted human ganglia. J Virol 2000;74:
17. Cohrs RJ, Gilden DH, Kinchington RR, Grinfeld E, Kennedy PG.
Varicella-zoster virus gene 66 transcription and translation in latently
infected human ganglia. J Virol 2003;77:6660–5.
18. Zerboni L, Ku CC, Jones CD, Zehnder JL, Arvin AM. Varicella-zoster
virus infection of human dorsal root ganglia in vivo. Proc Natl Acad
Sci U S A 2005;102:6490–5.
19. Cohrs RJ, Randall J, Smith J, et al. Analysis of individual human
trigeminal ganglia for latent herpes simplex virus type 1 and varicella-
zoster virus nucleic acids using real-time PCR. J Virol 2000;74:
20. Levin MJ, Cai GY, Manchak MD, Pizer LI. Varicella-zoster virusDNA
in cells isolated from human trigeminal ganglia. J Virol 2003;77:
21. Wang K, Lau TY, Morales M, Mont EK, Straus SE. Laser-capture
microdissection: refining estimates of the quantity and distribution
of latent herpes simplex virus 1 and varicella-zoster virus DNA in
human trigeminal ganglia at the single-cell level. J Virol 2005;79:
22. Lungu O, Panagiotidis CA, Annunziato PW, Gershon AA, Silverstein
SJ. Aberrant intracellular localization of varicella-zoster virus regu-
latory proteins during latency. Proc Natl Acad Sci U S A 1998;95:
S22 • CID 2007:44 (Suppl 1) • Dworkin et al.
23. Grinfeld E, Kennedy PG. Translation of varicella-zoster virus genes
during human ganglionic latency. Virus Genes 2004;29:317–9.
24. Hayward AR, Herberger M. Lymphocyte responses to varicella zoster
virus in the elderly. J Clin Immunol 1987;7:174–8.
25. Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence of
reinfection varicella-zoster virus. J Infect Dis 1983;148:200–5.
26. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella
boosts immunity to herpes-zoster: implications for mass vaccination
against chickenpox. Vaccine 2002;20:2500–7.
27. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with
children and protection against herpes zoster in adults: a case-control
study. Lancet 2002;360:678–82.
28. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to preventherpes
zoster and postherpetic neuralgia in older adults. N Engl J Med
29. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling
the impact of immunization on the epidemiology of varicella zoster
virus. Epidemiol Infect 2000;125:651–69.
30. Wreghitt TG, Whipp J, Redpath C, Hollingworth W. An analysis of
infection control of varicella-zoster virus infections in Addenbrooke’s
Hospital Cambridge over a 5-year period, 1987–92. Epidemiol Infect
31. Seward J. Epidemiology of varicella. In: Arvin AM, Gershon AA, eds.
Varicella-zoster virus: virology and clinical management. Cambridge:
Cambridge University Press, 2000:187–205.
32. Hope-Simpson RE. The nature of herpes zoster: a long-term study
and a new hypothesis. Proc R Soc Med 1965;58:9–20.
33. Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO. Pop-
ulation-based study of herpes zoster and its sequelae. Medicine
34. Donahue JG, Choo PW, Manson J, Platt R. The incidence of herpes
zoster. Arch Intern Med 1995;155:1605–9.
35. Schmader K, George LK, Hamilton JD. Racial differences in the oc-
currence of herpes zoster. J Infect Dis 1995;171:701–4.
36. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence
of postherpetic neuralgia after a first episode of herpes zoster: pro-
spective study with long term follow up. BMJ 2000;321:794–6.
37. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. In-
cidence of herpes zoster, 1997–2002. Epidemiol Infect 2005;133:
38. Yih WK, Brooks DR, Lett SM, et al. The incidence of varicella and
herpes zoster in Massachusetts as measured by the Behavioral Risk
Factor Surveillance System (BRFSS) during a period of increasing
varicella vaccine coverage, 1998–2003. BMC Public Health 2005;5:
39. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. Theincidence
of herpes zoster in a United States administrative database. J Gen
Intern Med 2005;20:748–53.
40. Jumaan AO, YuO, JacksonLA, BohlkeK,GalilK,SewardJF.Incidence
of herpes zoster, before and after varicella-vaccination-associatedde-
creases in the incidence of varicella, 1992–2002. J Infect Dis 2005;
41. Schuette MC, Hethcote HW. Modeling the effects of varicella vac-
cination programs on the incidence of chickenpox and shingles. Bull
Math Biol 1999;61:1031–64.
42. Edmunds J, Brisson M. The effect of vaccination on the epidemiology
of varicella zoster virus. J Infect 2002;44:211–9.
43. Klein NP, Holmes TH, Sharp MA, et al. Variability and gender dif-
ferences in memory T cell immunity to varicella-zoster virus in
healthy adults. Vaccine 2006;24:5913–8.
44. Head H, Campbell AW. The pathology of herpes zoster and itsbearing
on sensory localization. Brain 1900;23:353–523.
45. Denny-Brown D, Adams RD, Fitzgerald PJ. Pathologic features of
herpes zoster: a note on geniculate herpes. Arch Neurol Psychiatry
46. Liddell K. Post-herpetic pruritus. BMJ 1974;4:165.
47. Haanpa ¨a ¨ M, Ha ¨kkinen V, Nurmikko T. Motor involvement in acute
herpes zoster. Muscle Nerve 1997;20:1433–8.
48. Furuta Y, Fukuda S, Suzuki S, Takasu T, Inuyama Y, Nagashima K.
Detection of varicella-zoster virus DNA in patients with acute pe-
ripheral facial palsy by the polymerase chain reaction, and its use for
early diagnosis of zoster sine herpete. J Med Virol 1997;52:316–9.
49. Murakami S, Honda N, Mizobuchi M, Nakashiro Y, Hato N, Gyo K.
Rapid diagnosis of varicella zoster virus infection in acute facial palsy.
50. Stjernquist-Desatnik A, Skoog E, Aurelius E. Detection of herpes sim-
plex and varicella-zoster viruses in patients with Bell’s palsy by the
polymerase chain reaction technique. Ann Otol Rhinol Laryngol
51. Grogan PM, Gronseth GS. Practice parameter: steroids, acyclovir,and
surgery for Bell’s palsy (an evidence-based review). Neurology
52. Allen D, Dunn L. Aciclovir or valaciclovir for Bell’s palsy (idiopathic
facial paralysis) [review]. Cochrane Database Syst Rev 2004;3:
53. Holland NJ, Weiner M. Recent developments in Bell’s palsy. BMJ
54. Salinas RA, Alvarez G, Ferreira J. Corticosteroids for Bell’s palsy (id-
iopathic facial paralysis). Cochrane Database Syst Rev 2004;4:
55. Piercy J. Bell’s palsy. BMJ 2005;330:1374.
56. Sweeney CJ, Gilden DH. Ramsay Hunt syndrome.JNeurolNeurosurg
57. Grose C, Bonthius D, Afifi AK. Chickenpox and the geniculate gan-
glion: facial nerve palsy, Ramsay Hunt syndrome and acyclovir treat-
ment. Pediatr Infect Dis J 2002;21:615–7.
58. Osaki Y, Matsubayashi K, Okumiya K, Wada T, Doi Y. Polyneuritis
cranialis due to varicella-zoster virus in the absenceofrash.Neurology
59. Jude E, Chakraborty A. Left sixth cranial nerve palsy with herpes
zoster ophthalmicus. N Engl J Med 2005;353:e14.
60. Haanpa ¨a ¨ M, Dastidar P, Weinberg A, et al. CSF and MRI findings in
patients with acute herpes zoster. Neurology 1998;51:1405–11.
61. Echevarria JM, Casas I, Martinez-Martin P. Infections of the nervous
system caused by varicella-zoster virus: a review. Intervirology
62. Easton HG. Zoster sine herpete causing acute trigeminal neuralgia.
63. Barrett AP, Katelaris CH, Morris JG, Schifter M. Zoster sine herpete
of the trigeminal nerve. Oral Surg Oral Med Oral Pathol 1993;75:
64. Gilden DH, Wright RR, Schneck SA, Gwaltney JM, Mahalingam R.
Zoster sine herpete, a clinical variant. Ann Neurol 1994;35:530–3.
65. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam
R, Cohrs RJ. Neurologic complications of the reactivationofvaricella-
zoster virus. N Engl J Med 2000;342:635–45.
66. McKendrick MW, Care CC, Kudesia G, Bates CJ, Oxley MK, Eley A.
Is VZV reactivation a common cause of unexplained unilateral pain?
Results of a prospective study of 57 patients. J Infect 1999;39:209–12.
67. Guess HA, Broughton DD, Melton LJ, Kurland LT. Epidemiology of
herpes zoster in children and adolescents: a population-based study.
68. Petursson G, Helgason S, Gudmundsson S, Sigurdsson JA. Herpes
zoster in children and adolescents. Pediatr Infect Dis J 1998;17:905–8.
69. Kalman CM, LaskinOL.Herpeszosterandzosteriformherpessimplex
infections in immunocompetent adults. Am J Med 1986;81:775–8.
70. Ru ¨bben A, Baron JM, Grussendorf-Conen EI. Routine detection of
herpes simplex virus and varicella zoster virus by polymerase chain
reaction reveals that initial herpes zoster is frequently misdiagnosed
as herpes simplex. Br J Dermatol 1997;137:259–61.
71. Nahass GT, Goldstein BA, Zhu WY, Serfling U, Penneys NS, Leonardi
CL. Comparison of Tzanck smear, viral culture, and DNA diagnostic
Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S23
methods in detection of herpes simplex and varicella-zosterinfection.
72. Dahl H, Marcoccia J, Line A. Antigen detection: the method of choice
in comparison with virus isolation and serology for laboratory di-
agnosis of herpes zoster in human immunodeficiency virus-infected
patients. J Clin Microbiol 1997;35:347–9.
73. Jemsek J, Greenberg SB, Taber L, Harvey D, Gershon A, Couch RB.
Herpes zoster-associated encephalitis: clinicopathologic report of 12
cases and review of the literature. Medicine 1983;62:81–97.
74. Hughes BA, Kimmell DW, Aksamit AJ. Herpes-zoster associated me-
ningoencephalitis in patients with systemic cancer. Mayo Clin Proc
75. De La Blanchardiere A, Rozenberg F, Caumes E, et al. Neurological
complications of varicella-zoster virus infection in adults with human
immunodeficiency virus infection. Scand J Infect Dis 2000;32:263–9.
76. Amlie-Lefond C, Kleinschmidt-Demasters BK, Mahalingam R, Davis
LE, Gilden DH. The vasculopathyofvaricella-zostervirusencephalitis.
Ann Neurol 1995;37:784–90.
77. Aygun N, Finelli DA, Rodgers MS, Rhodes RH. Multifocal varicella-
zoster virus leukoencephalitis in a patient with AIDS: MR findings.
Am J Neuroradiol 1998;19:1897–9.
78. Kleinschmidt-DeMasters BK, Amlie-Lefond C, Gilden DH. The pat-
terns of varicella zoster virus encephalitis. Hum Pathol 1996;27:
79. Poscher ME. Successful treatment of varicella-zoster virus menin-
goencephalitis in patients with AIDS: report of 4 cases and review.
80. Verghese A, Sugan AM. Herpes zoster ophthalmicus and granulo-
malous angiitis: an ill-appreciated cause of stroke. J Am Geriatr Soc
81. Moriuchi H, Rodriguez W. Role of varicella-zoster virus in stroke
syndromes. Pediatr Infect Dis J 2000;19:648–53.
82. Eidelberg D, Sotrel A, Horoupian DS, Neumann PE, Pumarold-Sune
T, Price RW. Thrombotic cerebral vasculopathy associatedwithherpes
zoster. Ann Neurol 1986;19:7–14.
83. Reshef E, Greenberg SB, Jankovic J. Herpes zoster ophthalmicus fol-
lowed by contralateral hemiparesis: report of two cases and review
of literature. J Neurol Neurosurg Psychiatry 1985;48:122–7.
84. Gilden DH, Beinlick BR, Rubinstein EM, et al. Varicella-zoster virus
myelitis: an expanding spectrum. Neurology 1994;44:1818–23.
85. Devinsky O, Cho ES, Petito CK, Price RW. Herpes zoster myelitis.
86. Heller HM, Carnevale NT, Steigbigel RT. Varicella zoster virus trans-
verse myelitis without cutaneous rash. Am J Med 1990;88:550–1.
87. Grant AD, Fox JD, Brink NS, Miller RF. Detection of varicella-zoster
virus DNA using the polymerase chain reaction in an immunocom-
promised patient with transverse myelitis secondary to herpes zoster.
Genitourin Med 1993;69:273–5.
88. Manian FA, Kindred M, Fulling KH. Chronic varicella-zoster virus
myelitis without cutaneous eruption in a patient with AIDS: report
of a fatal case. Clin Infect Dis 1995;21:986–8.
89. Hwang YM, Lee BI, Chung JW, Ahn JH, Kim KW, Kim DI. A case
of herpes zoster myelitis: positivemagneticresonanceimagingfinding.
Eur Neurol 1991;31:164–7.
90. Engstrom RE, Holland GN, Maryolis TP, et al. The progressive outer
retinal necrosis syndrome: a variant of necrotizing herpetic retinop-
athy in patients with AIDS. Ophthalmology 1994;101:1488–502.
91. Moorthy RS, Weinberg DV, Teich SA, et al. Management of varicella
zoster virus retinitis in AIDS. Br J Ophthalmol 1997;81:189–94.
92. Ormerod LD, Larkin JA, Margo CA, et al. Rapidlyprogressiveherpetic
retinal necrosis: a blinding disease characteristic of advanced AIDS.
Clin Infect Dis 1998;26:34–45.
93. Batisse D, Eliaszewicz M, Zazoan L, Baudrimont M, Pialoux G, Du-
pont B. Acute retinal necrosis in the course of AIDS: study of 26
cases. AIDS 1996;10:55–60.
94. Kashiwase M, Sata T, Yamauchi Y, et al. Progressive outer retinal
necrosis caused by herpes simplex virus type 1 in a patient with
acquired immunodeficiency syndrome. Ophthalmology 2000;107:
95. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster.
96. Arani RB, Soong SJ, Weiss HL, et al. Phase specific analysis of herpes
zoster associated pain data: a new statistical approach. Stat Med
97. Desmond RA, Weiss HL, Arani RB, et al. Clinical application for
change-point analysis of herpes zoster pain. J Pain Symptom Manage
98. Jung BF, Johnson RW, Griffin DRJ, Dworkin RH. Risk factors for
postherpetic neuralgia in patients with herpes zoster. Neurology
99. Bowsher D. The lifetime occurrence of herpes zoster and prevalence
of postherpetic neuralgia: a retrospective survey in an elderly pop-
ulation. Eur J Pain 1999;3:335–42.
100. McKendrick MW, Wood MJ. Acyclovir and post-herpetic neuralgia:
two other participating centres report different results. BMJ 1995;
101. Meister W, Neiß A, Gross G, et al. A prognostic score for postherpetic
neuralgia in ambulatory patients. Infection 1998;26:359–63.
102. Whitley RJ, Weiss HL, Soong SJ, Gnann JW. Herpes zoster: risk cat-
egories for persistent pain. J Infect Dis 1999;179:9–15.
103. Dworkin RH, Schmader KE. The epidemiology and natural history
of herpes zoster and postherpetic neuralgia.In: WatsonCPN,Gershon
AA, eds. Herpes zoster and postherpetic neuralgia. 2nd ed. New York:
Elsevier Press, 2001:39–64.
104. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable
nociceptors and deafferentation. Neurobiol Dis 1998;5:209–27.
105. Rowbotham MC, Baron R, Petersen KL, Fields HL. Spectrum of pain
mechanisms contributing to PHN. In: Watson CPN, Gershon AA,
eds. Herpes zoster and postherpetic neuralgia. 2nd ed. New York:
Elsevier Press, 2001:183–95.
106. Woolf CJ. Pain: moving from symptom control toward mechanism-
specific pharmacologic management. Ann Intern Med 2004;140:
107. Petersen KL, Fields HL, Brennum J, Sandroni P, Rowbotham MC.
Capsaicin evoked pain and allodynia in post-herpetic neuralgia. Pain
108. Watson CPN, Deck JH, Morshead C, van der Kooy D, Evans RJ. Post-
herpetic neuralgia: further post-mortem studies of cases with and
without pain. Pain 1991;44:105–17.
109. Rowbotham MC, Yosipovitch G, Connolly MK, Finlay D, Forde G,
Fields HL. Cutaneous innervation density in the allodynic form of
postherpetic neuralgia. Neurobiol Dis 1996;3:205–14.
110. Oaklander AL, Romans K, Horasek S, Stocks A, Hauer P, Meyer RA.
Unilateral postherpetic neuralgia is associated with bilateral sensory
neuron damage. Ann Neurol 1998;44:789–95.
111. Gilron I, Bailey JM, Dongsheng T, Holden RR, Weaver DF, Houlden
RL. Morphine, gabapentin,ortheircombinationforneuropathicpain.
N Engl J Med 2005;352:1324–34.
112. Surman OS, Flynn T, Schooley RT, et al. A double-blind, placebo-
controlled study of oral acyclovir in postherpetic neuralgia. Psycho-
113. Acosta EP, Balfour HH Jr. Acyclovir for treatment of postherpetic
neuralgia: efficacy and pharmacokinetics. Antimicrob Agents Che-
114. Gilden DH, Cohrs RJ, Mahalingam R. VZV vasculopathy and post-
herpetic neuralgia: progress and perspective on antiviraltherapy.Neu-
115. Quan D, Hammack BN, Kittelson J, Gilden DH. Improvement of
postherpetic neuralgia after treatment with intravenous acyclovir fol-
lowed by oral valacyclovir. Arch Neurol 2006;63:940–2.
116. Oaklander AL, Bowsher D, Galer BS, Haanpa ¨a ¨ ML,JensenMP.Herpes
zoster itch: preliminary epidemiologic data. J Pain 2003;4:338–43.
S24 • CID 2007:44 (Suppl 1) • Dworkin et al.
117. Oaklander AL, Cohen SP, Raju SV. Intractable postherpetic itch and
cutaneous deafferentation after facial shingles. Pain 2002;96:9–12.
118. Lancaster T, Silagy C, Gray S. Primary care management of acute
herpes zoster: systematic review of evidence from randomized con-
trolled trials. Br J Gen Pract 1995;45:39–45.
119. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir
therapy accelerates pain resolution in patients with herpes zoster: a
meta-analysis of placebo-controlled trials. Clin Infect Dis 1996;22:
120. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating
herpes zoster with oral acyclovir in preventing postherpeticneuralgia:
a meta-analysis. Arch Intern Med 1997;157:909–12.
121. Alper BS, Lewis PR. Does treatment of acute herpes zoster prevent
or shorten postherpetic neuralgia? A systematic review of the litera-
ture. J Fam Pract 2000;49:255–64.
122. British Society for the Study of Infection. Guidelines for the man-
agement of shingles: report of a working group of the British Society
for the Study of Infection. J Infect 1995;30:193–200.
123. Peyramond D, Chidiac C, Lucht F, et al. Management of infections
due to the varicella-zoster virus. Eur J Dermatol 1998;8:397–402.
124. Johnson R, Patrick D, eds. Improving the management of varicella,
herpes zoster and zoster-associated pain. Recommendations from the
IHMF Management Strategies Workshop. International Herpes Man-
agement Forum, 2002. Available at: http://www.ihmf.org/library/
monograph/m_11.pdf. Accessed 17 July 2006.
125. Gross G, Scho ¨fer H, Wassilew S, et al. Herpes zoster guideline of the
German Dermatology Society (DDG). J Clin Virol 2003;26:277–89.
126. Cook DJ, Greengold NL, Ellrodt AG, Weingarten SR. The relation
between systematic reviews and practice guidelines. Ann Intern Med
127. Slavin RE. Best evidence synthesis: an intelligent alternative to meta-
analysis. J Clin Epidemiol 1995;48:9–18.
128. Rychetnik L, Hawe P, Waters E, Barratt A, Frommer M. A glossary
for evidence based public health. J Epidemiol Community Health
129. Coplan PM, Schmader K, Nikas A, et al. Development of a measure
of the burden of pain due to herpes zoster and postherpetic neuralgia
for prevention trials: adaptation of the Brief Pain Inventory. J Pain
130. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in
acute herpes zoster. BMJ 1986;293:1529–32.
131. McKendrick MW, McGill JI, Wood MJ. Lack of effect of acyclovir on
postherpetic neuralgia. BMJ 1989;298:431.
132. Huff JC, Bean B, Balfour HH Jr, et al. Therapy of herpes zoster with
oral acyclovir. Am J Med 1988;85(Suppl 2A):84–9.
133. Huff JC, Drucker JL, Clemmer A, et al. Effect of oral acyclovir on
pain resolution in herpes zoster: a reanalysis. J Med Virol 1993;Suppl
134. Wood MJ, Ogan PH, McKendrick MW, Care CD, McGill JI, Webb
EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am
J Med 1988;85(Suppl 2A):79–83.
135. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes
zoster in general practice. N Z Med J 1989;102:93–5.
136. Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus.
Curr Eye Res 1991;10(Suppl):177–82.
137. Degreef H. Famciclovir, a new oral antiherpes drug: results of the
first controlled clinical study demonstrating its efficacy and safety in
the treatment of uncomplicated herpes zoster in immunocompetent
patients. Int J Antimicrob Agents 1994;4:241–6.
138. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir forthetreatment
of acute herpes zoster: effects on acute disease and postherpetic neu-
ralgia: a randomized, double-blind, placebo-controlled trial. Ann In-
tern Med 1995;123:89–96.
139. Dworkin RH, Boon RJ, Griffin DR, Phung D. Postherpetic neuralgia:
impact of famciclovir, age, rash severity and acute pain in herpes
zoster patients. J Infect Dis 1998;178(Suppl 1):S76–80.
140. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ.
Valaciclovir compared with acyclovir for improved therapy for herpes
zoster in immunocompetent adults. Antimicrob Agents Chemother
141. Shen MC, Lin HH, Lee SSJ, Chen YS, Chiang PC, Liu YC. Double-
blind, randomized, acyclovir-controlled, parallel-group trial compar-
ing the safety and efficacy of famciclovir and acyclovir in patients
with uncomplicated herpes zoster. J Microbiol Immunol Infect 2004;
142. Lin WR, Lin HH, Lee SSJ, et al. Comparative study of the efficacy
and safety of valaciclovir versus acyclovir in the treatment of herpes
zoster. J Microbiol Immunol Infect 2001;34:138–42.
143. Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times
daily famciclovir compared with aciclovir for the oral treatment of
herpes zoster in immunocompetent adults: a randomized, multicen-
ter, double-blind clinical trial. J Clin Virol 2004;29:248–53.
144. Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir
for improved therapy of herpes zoster in immunocompetentpatients:
results of a randomized, double-blind, multicentered study. Antiviral
145. Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir
for herpes zoster: a survey study on postherpetic neuralgia. Antiviral
146. Wassilew SW. Brivudin compared with famciclovir in the treatment
of herpes zoster: effects in acute disease and chronic pain in im-
munocompetent patients. A randomized, double-blind,multinational
study. J Eur Acad Dermatol Venereol 2005;19:47–55.
147. Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an
overview of clinical trials with acyclovir. Scand J Infect Dis Suppl
148. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without
prednisone for the treatment of herpes zoster: a randomized,placebo-
controlled trial. Ann Intern Med 1996;125:376–83.
149. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. An-
tiviral therapy for herpes zoster: randomized, controlled clinical trial
of valacyclovir and famciclovir therapy in immunocompetentpatients
50 years and older. Arch Fam Med 2000;9:863–9.
150. Wood MJ, Shukla S, Fiddian AP, Crooks RJ. Treatment of acuteherpes
zoster: effect of early (!48 h) versus late (48–72 h) therapy with
acyclovir and valaciclovir on prolonged pain. J Infect Dis 1998;
151. Decroix J, Partsch H, Gonzalez R, et al. Factors influencing pain
outcome in herpes zoster: an observational study with valaciclovir. J
Eur Acad Dermatol Venereol 2000;14:23–33.
152. Kurokawa I, Kumano K,MurakawaK.Clinicalcorrelatesofprolonged
pain in Japanese patients with herpes zoster. J Int Med Res 2002;30:
153. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK,
Crooks J. A randomized trial of acyclovir for 7 days or 21 days with
and without prednisolone for treatment of acute herpes zoster.NEngl
J Med 1994;330:896–900.
154. So ¨ltz-Szo ¨ts J, Tyring S, Andersen PL, et al. A randomized controlled
trial of acyclovir versus netivudine for treatment of herpes zoster. J
Antimicrob Chemother 1998;41:549–56.
155. Dworkin RH, Schmader KE. Treatment and prevention of posther-
petic neuralgia. Clin Infect Dis 2003;36:877–82.
156. McQuay HJ, Trame `r M, Nye BA, Carroll D, Wiffen PJ, Moore RA.
A systematic review of antidepressants in neuropathic pain. Pain
157. Finnerup NB,Otto M,McQuay HJ,JensenTS,SindrupSH.Algorithm
for neuropathic pain treatment: an evidence based proposal. Pain
158. Bowsher D. The effects of pre-emptive treatment of postherpeticneu-
ralgia with amitriptyline: a randomized, double-blind, placebo-con-
trolled trial. J Pain Symptom Manage 1997;13:327–31.
159. Dworkin RH. Prevention of postherpetic neuralgia. Lancet 1999;353:
160. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of pa-
Management of Herpes Zoster • CID 2007:44 (Suppl 1) • S25
roxetine and nortriptyline in depressed patients with ischemic heart
disease. JAMA 1998;279:287–91.
161. Ray WA, Meredith S, Thapa BP, Hall K, Murray KT. Cyclic antide-
pressants and the risk of sudden cardiac death. Clin Pharmacol Ther
162. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neu-
ropathic pain: diagnosis, mechanisms, and treatment recommenda-
tions. Arch Neurol 2003;60:1524–34.
163. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended
release in the treatment of painful diabetic neuropathy: a double-
blind, placebo-controlled study. Pain 2004;110:697–706.
164. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs.
placebo in patients with painful diabetic neuropathy. Pain 2005;116:
165. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med
166. Eisenberg E, McNichol ED, Carr DB. Efficacy and safety of opioid
agonists in the treatment of neuropathic pain of nonmalignantorigin:
systematic review and meta-analysis of randomized controlled trials.
167. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain:
a randomized trial in postherpetic neuralgia. Neurology 1998;50:
168. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus
antidepressants in postherpetic neuralgia:arandomized,placebo-con-
trolled trial. Neurology 2002;59:1015–21.
169. Dworkin RH. Strategies for the prevention of neuropathic pain. In:
Program and abstracts of Expanding Vistas in Neuropathic Pain, an
official satellite of the 11th WorldCongressonPain(Uluru,Australia).
Seattle: International Association for the Study of Pain Neuropathic
Pain Special Interest Group, 2005:39.
170. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic
neuralgia: a randomized, double-blind, placebo-controlled trial. Pain
171. Rowbotham MC, Harden N, Stacey B, Bernstein P, Magnus-Miller L.
Gabapentin for the treatment of postherpetic neuralgia:a randomized
controlled trial. JAMA 1998;280:1837–42.
172. Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: a random-
ised, double blind, placebo controlled study. Pain 2001;94:215–24.
173. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treat-
ment of postherpetic neuralgia: a randomized, placebo-controlled
trial. Neurology 2003;60:1274–83.
174. Sabatowski R, Ga ´lvez R, Cherry DA, et al. Pregabalin reduces pain
and improves sleep and mood disturbances in patients with post-
herpetic neuralgia: results of a randomised,placebo-controlledclinical
trial. Pain 2004;109:26–35.
175. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy
of pregabalin in neuropathicpainevaluatedina12-week,randomised,
double-blind, multicentre, placebo-controlled trial of flexible- and
fixed-dose regimens. Pain 2005;115:254–63.
176. van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Ri-
gaudy L. Efficacy and tolerability of twice-daily pregabalin fortreating
pain and related sleep interference in postherpetic neuralgia: a 13-
week, randomized trial. Curr Med Res Opin 2006;22:375–84.
177. Berry JD, Petersen KL. A single dose of gabapentin reduces acute
pain and allodynia in patients with herpes zoster. Neurology 2005;
178. Brentjens MH, Torres G, He J, Lee PC, Tyring SK. Reduction of
postherpetic neuralgia in herpes zoster: a study of the effects of ga-
bapentin with valacyclovir during acute zoster outbreaks. Presented
at: Annual Meeting of the American Academy of Dermatology (San
Francisco, March 2003).
179. Dahl JB, Mathiesen O, Møiniche S. ‘Protective premedication:’ an
option with gabapentin and related drugs? A review of gabapentin
and pregabalin in the treatment of post-operative pain. Acta Anaes-
thesiol Scand 2004;48:1130–6.
180. Kuraishi Y, Takasaki I, Nojima H, Shiraki K, Takahata H. Effects of
the suppression of acute pain by gabapentin and amitriptyline on the
incidence of delayed postherpetic pain in mice. Life Sci 2004;74:
181. Rowbotham MC, Young JP Jr, Sharma U. Pregabalin significantly
reduces neuropathic pain associated with diabetic peripheral neurop-
athy and postherpetic neuralgia by day 3 of treatment. In: Program
and abstracts of Neuropathic Pain: Changing Paradigms in Diagnosis
and Treatment (Madrid). Seattle: International Association for the
Study of Pain Neuropathic Pain Special Interest Group, 2004:48.
182. Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks
in herpes zoster and postherpetic neuralgia. Pain 2000;87:121–9.
183. Kumar V, Krone K, Mathieu A. Neuraxial and sympathetic blocks in
herpes zoster and postherpetic neuralgia: an appraisal of current evi-
dence. Reg Anesth Pain Med 2004;29:454–61.
184. Opstelten W, van Wijck AJM, Stolker RJ. Interventions to prevent
postherpetic neuralgia: cutaneous and percutaneous techniques. Pain
185. van Wijck AJM, Opstelten W, Moons KGM, et al. The PINE study
of epidural steroids and local anaesthetics to prevent postherpetic
neuralgia: a randomised controlled trial. Lancet 2006;367:219–24.
186. Pasqualucci A, Pasqualucci V, Galla F, et al. Prevention of post-her-
petic neuralgia: acyclovir and prednisolone versus epidural local an-
esthetic and methylprednislone. Acta Anaesthesiol Scand 2000;44:
187. Manabe H, Dan K, Hirata K, et al. Optimum pain relief with con-
tinuous epidural infusion of local anesthetics shortens the duration
of zoster-associated pain. Clin J Pain 2004;20:302–8.
188. Hu ¨gler P, Siebrecht P, Hoffmann K, et al. Prevention of postherpetic
neuralgia with varicella-zoster hyperimmune globulin. Eur J Pain
189. Ahmed HE, Craig WF, White PF, et al. Percutaneous electrical nerve
stimulation: an alternative to antiviral drugs for acute herpes zoster.
Anesth Analg 1998;87:911–4.
190. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic
review of topical capsaicin for the treatment of chronic pain. BMJ
191. Haanpa ¨a ¨ M, Laippala P, Nurmikko T. Allodynia and pinprick hy-
pesthesia in acute herpes zoster, and the development of postherpetic
neuralgia. J Pain Symptom Manage 2000;20:50–8.
192. Watson CPN, Vernich L, Chipman M, Reed K. Nortriptyline versus
amitriptyline in postherpetic neuralgia: a randomized trial.Neurology
193. Serota FT, Starr SE, Bryan CK, Koch PA, Plotkin SA, August CS.
Acyclovir treatment of herpes zoster infections use in children un-
dergoing bone marrow transplant. JAMA 1982;247:2132–6.
194. Balfour HH, Bean B, Laskin OL, et al. Acyclovir halts progression of
herpes zoster in immunocompromised patients. N Engl J Med 1983;
195. Meyers JD, Wade JC, Shepp DH, Newton B. Acyclovir treatment of
varicella-zoster virus infection in the compromised host. Transplan-
196. Shepp DH, Dandliker PS, Meyers JD. Treatment of varicella-zoster
infection in severely immunocompromised patients: a randomized
comparison of acyclovir and vidarabine. N Engl J Med 1986;314:
197. Ljungman P, Lonnqvist B, Ringden O, Skinhoj P, Gahrton G. A ran-
domized trial of oral versus intravenous acyclovir for treatment of
herpes zoster in bone marrow transplant recipients. Bone Marrow
198. Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman
RL. A randomized, double-blind trial of famciclovir versus acyclovir
for the treatment of localized dermatomal herpes zoster in immu-
nocompromised patients. Cancer Invest 2001;19:13–22.
199. Brentjens MH, Torres G, He J, Lee PC, Tyring SK. A double-blind
randomized study of the use of 2 grams vs. 1 gram valacyclovir TID
for 7 days in the treatment of acute herpes zoster in immunocom-
S26 • CID 2007:44 (Suppl 1) • Dworkin et al. Download full-text
promised individuals. Presented at: Annual Meeting of the American
Academy of Dermatology (San Francisco, March 2003).
200. Wutzler P, de Clercq E, Wutke K, Fa ¨rber I. Oral brivudin vs. intra-
venous acyclovir in the treatment of herpes zoster in immunocom-
promised patients: a randomized double-blind trial. J MedVirol1995;
201. Walton RC, Reed KL. Herpes zoster ophthalmicus following bone
marrow transplantation in children. Bone Marrow Transplant 1999;
202. Bodsworth NJ, Boag F, Burdge D, et al. Evaluation of sorivudine(BV-
araU) versus acyclovir in the treatment of acute localizedherpeszoster
in human immunodeficiency virus-infected adults. J Infect Dis 1997;
203. Gnann JW Jr, Crumpacker CS, Lalezari JP, et al. Sorivudine versus
acyclovir for treatment of dermatomal herpes zoster in human im-
munodeficiency virus-infected patients: results from a randomized,
controlled clinical trial. Antimicrob Agents Chemother 1998;42:
204. Sullivan M, Skiest D, Signs D, Young C. Famciclovir in the manage-
ment of acute herpes zoster in HIV+ patients. Presented at: Fourth
Conference on Retroviruses and Opportunistic Infections (Washing-
ton, DC, 22–26 January 1997).
205. Cobo LM. Corneal complications of herpes zosterophthalmicus.Cor-
206. Holland GN. Acquired immune deficiency syndrome and ophthal-
mology: the first decade. Am J Ophthalmol 1992;114:86–95.
207. Mahalingam R, Wellish M, Wolf W, et al. Latent varicella-zoster viral
DNA in human trigeminal and thoracic ganglia. N Engl J Med
208. Kurland L. Descriptive epidemiology of selected neurological and
myopathic disorders with particularreferencetoasurveyinRochester,
Minnesota. J Chronic Dis 1958;8:378–418.
209. Ragozzino MW, Melton LF III, Kurland LT. Population-based study
of herpes zoster and its sequelae. Medicine 1982;61:310–6.
210. Liesegang TJ. The varicella-zoster virus: systemic and ocular features.
J Am Acad Dermatol 1984;11:165–91.
211. Weller TH. Varicella-zoster virus: history, perspectives, and evolving
concerns. Neurology 1995;45(Suppl 8):S9–10.
212. Oxman MN, Williams HM, Levin MJ, et al. Efficacy of zoster vaccine
according to dermatome region. Presented at: 45th Annual Intersci-
ence Conference on Antimicrobial Agents and Chemotherapy(Wash-
ington, DC, 16–19 December 2005).
213. Miserocchi E, Waheed NK, Dios E, et al. Visual outcome in herpes
simplex virus and varicella zoster virus uveitis: a clinical evaluation
and comparison. Ophthalmology 2002;109:1532–7.
214. Womack LW, Liesegang TJ. Complications of herpes zoster ophthal-
micus. Arch Ophthalmol 1983;101:42–5.
216. Liesegang TJ. Varicella-zoster virus eye disease. Cornea 1999;18:
217. Pavan-Langston D. Ophthalmic zoster. In: Watson CPN, Gershon A.
Herpes zoster and postherpetic neuralgia. Amsterdam: Elsevier, 2001:
218. Pavan-Langston D. Viral disease of the ocular anterior segment: basic
science and clinical disease. In: Foster S, Azar D, Dohlman C. The
Cornea. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005:
219. Cobo L, Foulks G, Liesegang T. Oral acyclovir in the treatment of
acute herpes zoster ophthalmicus. Ophthalmology 1986;93:763–70.
220. Colin J, Prisant O, Cochener B, Lescale O, Rolland B, Hoang-Xuan
T. Comparison of the efficacy and safety of valaciclovir and acyclovir
for the treatment of herpes zoster ophthalmicus. Ophthalmology
221. Tyring S, Engst R, Corriveau C, et al. Famciclovir for ophthalmic
zoster: a randomised aciclovir controlledstudy.BrJOphthalmol2001;
222. Severson EA, Baratz KH, Hodge DO, Burke JP. Herpes zosterophthal-
micus in Olmsted County, Minnesota: have systemic antivirals made
a difference? Arch Ophthalmol 2003;121:386–90.
223. Tenicela R, Lovasik D, Eaglstein W. Treatment of herpes zoster with
sympathetic blocks. Clin J Pain 1985;1:63–7.
224. Harding SP, Lipton JR, Wells JCD, Campbell JA. Relief of acute pain
in herpes zoster ophthalmicus by stellate ganglion block. BMJ 1986;
225. Nurmikko T, Ra ¨sa ¨nen A, Ha ¨kkinen V. Clinicalandneurophysiological
observations on acute herpes zoster. Clin J Pain 1990;6:284–90.
226. Johnston WH, Holland GN, Engstrom RE, Rimmer S. Recurrence of
presumed varicella-zoster virus retinopathy in patients with acquired
immune deficiency syndrome. Am J Ophthalmol 1993;116:42–50.
227. Galindez OA, Sabates NR, Whitacre MW, Sabates FN. Rapidly pro-
gressive outer retinal necrosis caused by varicella zoster virus in a
patient infected with human immunodeficiency virus. Clin Infect Dis
228. Spaide RF, Martin DF, Teich SA, Katz A, Toth I. Successful treatment
of progressive outer retinal necrosis syndrome. Retina 1996;16:479–87.
229. Meffert SA, Kertes PJ, Lim PL, Conway MD, Peyman GA. Successful
treatment of progressive outer retinal necrosis using high-dose in-
travitreal ganciclovir. Retina 1997;17:560–2.
230. Perez-Blazquez E, Traspas R, Mendez MI, Montero M. Intravitreal
ganciclovir treatment in progressive outer retinal necrosis. Am J
231. Ciulla TA, Rutledge BK, Morley MG, Duker JS. The progressive outer
retinal necrosis syndrome: successful treatment with combinationan-
tiviral therapy. Ophthalmic Surg Lasers 1998;29:198–206.
232. Scott IU, Luu KM, Davis JL. Intravitreal antivirals in the management
of patients with acquired immunodeficiency syndrome with progres-
sive outer retinal necrosis. Arch Ophthalmol 2002;120:1219–22.
233. Schliefer K, Gumbel HO, Rockstroh JK, Spengler U. Management of
progressive outer retinal necrosis with cidofovir in a human immu-
nodeficiency virus–infected patient. Clin Infect Dis 1999;29:684–5.
234. Zambarakji HJ, Obi AA, Mitchell SM. Successfultreatmentofvaricella
zoster virus retinitis with aggressive intravitreal and systemic antiviral
therapy. Ocul Immunol Inflamm 2002;10:41–6.
235. Palay DA, Sternberg P Jr, Davis J, et al. Decrease in the risk of bilateral
acute retinal necrosis by acyclovir therapy. Am J Ophthalmol 1991;
236. Wenger NS, Shekelle PG. Assessing care of vulnerable elders: ACOVE
project overview. Ann Intern Med 2001;135:642–6.
237. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling
the concepts of disability, frailty, and comorbidity: implications for
improved targeting and care. J Gerontol A Biol Sci Med Sci 2004;59:
238. Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Phar-
239. Rochon PA, Gurwitz JH. Drug therapy. Lancet 1995;346:32–6.
240. Weiner D, Peterson B, Lad K, McConnell E, Keefe F. Pain in nursing
home residents: an exploration of prevalence, staff perspectives, and
practical aspects of measurement. Clin J Pain 1999;15:92–101.
241. Schmader KE, Twersky JT. Herpes zoster, cellulitis, and scabies. In:
Yoshikawa TT, Ouslander JG, eds. Infectionmanagementforgeriatrics
in long-term care facilities. New York: Marcel-Dekker, 2002:283–305.
242. Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD,
Andrews EB. Monitoring pregnancy outcomes after prenatal drug
exposure through prospective pregnancy registries: a pharmaceutical
company commitment. Am J Obstet Gynecol 2000;182:159–63.
243. Gnann JW Jr. Varicella-zoster virus: atypical presentations and un-
usual complications. J Infect Dis 2002;186(Suppl 1):S91–8.